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Abstract 
 
 Amyotrophic Lateral Sclerosis is a fatal neurodegenerative disease that leads to progressive 
paralysis due to motorneuron degeneration and eventually death due to respiratory failure. No effective 
treatments are currently available and, even though several cellular pathways are altered during the 
disease course, the initiating event that triggers motorneuron degeneration is still unclear. The majority of 
ALS cases are sporadic, however approximately 10% are familial and several disease-linked genes have 
been identified. Ten years ago a mutation in the gene encoding for VAPB was associated with a 
dominantly inherited form of ALS (termed ALS8). Moreover, sporadic ALS patients have reduced levels 
of the endogenous protein. VAPB belongs, along with its homologue VAPA, to the VAP protein family: 
ER resident tail anchored proteins that, thanks to their binding partners, are involved in several cellular 
functions like lipid transport, ER stress and membrane contact site formation. The ALS-associated 
mutation P56S dramatically alters VAPB structure, thus preventing the binding to its physiological 
interactors and causing its aggregation. However, is has been unclear whether ALS8 is due to a gain or 
loss of function mechanism: P56S-generated inclusions could be directly toxic or reduced levels of the 
endogenous protein might underlie its pathogenicity.  
 To understand the pathogenic mechanism of this mutant I used two complementary approaches: I 
analyzed cellular models that either express moderate levels of P56S-VAPB or have reduced levels of the 
endogenous protein. As already observed in epithelial cells, under basal conditions the mutant protein can 
be easily degraded by the proteasome in motorneuronal cells. However, following autophagy stimulation 
it can became a substrate also of this pathway. Moreover, the presence of P56S-VAPB doesn’t interfere 
with general proteostasis or protein transport. These results prompted us to investigate VAPB-
downregulated motorneuronal cells. In this model, we saw an increase in the phosphoinositide PI4P in the 
Golgi and a reduction in neurite extension following differentiation. 
 The results indicate that P56S-VAPB inclusions are not toxic, while reduced levels of the 
endogenous VAPB can alter motorneuronal homeostasis. Therefore, these findings suggest that ALS8 
pathogenicity is not due to toxic gain of function of the mutant but rather to a loss of function of the 
endogenous protein. This finding is relevant not only for ALS8, but also for forms of sporadic ALS, in 
which VAPB levels are reduced. 
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List of Abbreviations 
 
Abbreviation Full name 
ADP Adenosinediphosphate 
ALS Amyotrophic Lateral Sclerosis 
ATF6 Activating Transcription Factor 6 
ATP Adenosine tri phosphate 
BSA Bovine Serum Albumine 
CERT Ceramide Transfer Protein 
ChAT Choline Acetyl Transferase 
CHX Cycloheximide 
CNS Central Nervous System 
DAG DiacylGlycerol 
DMEM Dulbecco Modified Eagle Medium 
DMEM/F12 Dulbecco Modified Eagle Medium/F12 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DRP Dipeptide Repeat Proteins  
EBSS Earle's Buffered Salt Solution 
Eph Ephrine 
ER Endoplasmic Reticulum 
ERAD ER-Associated Degradation 
ERGIC ER-Golgi intermediate compartment  
fALS Familial Amyotrophic Lateral Sclerosis 
FFAT Two Fenilalanies in an Acidic Tract 
FTD Fronto Temporal Dementia 
FUS Fused in Sarcoma 
GA Glutaraldheyde 
GAP43 Growth Associated Protein 43 
GDP Guanosine diphosphate 
GEF GDP/GTP Exchange Factor 
GFP Green Fluorescent Protein 
GM130 Golgi Matrix protein of 130 KDa 
GSL GlycoSphingoLipid 
GTP Guanosine-5'-triphosphate  
HDAC Hystone Deacetylase 
IF Immunofluorescence 
IRE1 Inositol Requiring enzyme 1 
LAMP1 Lysosome Associated Membrane Protein 1 
LE Late Endosome 
LTP Lipid Transfer Protein 
MAM Mitocontrial Associated Membrane 
MCS Membrane Contact Site 
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Miro-1 Mitochondrial Rho GTPase-1 
MN Motor Neuron 
MND Motor Neuron Disease 
MOM Mitochondrial Outer Membrane 
MSP Major Sperm Protein 
NEAA Non Essential Amino Acids 
OD Optical Density 
OSER Organized Smooth ER 
P/S Penicillin/Streptomycin 
PAGE PolyAcrilamide Gel Electrophoresis 
PBS Phosphate Buffered Saline 
PERK Protein kinase RNA-like Endoplasmic Reticulum Kinase 
PH Pleckstrin Homology 
PI Phosphatidil Inosytol 
PI4K phosphatidylinositol 4-kinase 
PI4P Phospahtidil Inositol 4 monophosphate 
PLS Primary Lateral Sclerosis 
PMA Progressive Muscular Atrophy 
RAN Repeat-Associated Non-ATG translation  
RNA Ribonucleic acid  
RT Room Temperature 
Sac1 Suppressor of Actin 1 
sALS Sporadic Amyotrophic Lateral Sclerosis 
SDS Sodium Dodecyl Sulphate 
shRNA short haipin RNA 
siRNA silencing RNA 
SM Sphingomyelin 
SMA Spinal Muscular Atrophy 
SOD1 Superoxide Dismutase 1 
SpMN Spinal Motor Neuron 
SR Serine Repeat 
START Steroidogenic Acute Regulatory protein (StAR)-Related lipid Transfer  
TBS Tris Buffered Saline 
TDP43 TAR DNA-binding protein 43  
TRAK Trafficking Kinesin Protein-1 
UPR Unfolded Protein Response 
UPS Ubiquitin Proteasome System 
VAPA (Vesicle-associated membrane protein)-Associated Protein A 
VAPB (Vesicle-associated membrane protein)-Associated Protein B 
VSVG Vesicular Stomatitis Virus G glycoprotein 
WB Western Blot 
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1. Introduction 
 
1.1. Motor Neuron Diseases 
 
Motor Neuron Diseases (MND) are a heterogeneous group of neurodegenerative disorders 
characterized by progressive and selective injury and death of motor neurons (MNs). At present, 
unfortunately, there are no effective drugs to alter the course of these diseases, which are widespread and 
of fatal outcome.  
MNs are neuronal cells located in the central nervous system (CNS). There are two main types of 
MNs: upper MNs and lower MNs. Upper MN cell bodies are located in the pre-motor and primary motor 
region of the cerebral cortex, also known as the “motor strip”. They make glutammatergic synaptic 
connections with lower MNs, whose cell bodies are located in the brainstem and in the ventral horn of the 
spinal cord. Lower MNs make cholinergic connections with their target muscles. Spinal motor neurons 
(SpMNs) are located in the ventral horn of the spinal cord and control effector muscles in the periphery. 
In mammals, their axons can extend through several meters, making them the longest known cell type.  
Due to their highly polarized morphological features, topological constraints and post-mitotic 
nature, MNs are uniquely vulnerable to pathogenic stimuli and dependent on the maintenance of a 
balanced cellular homeostasis, thus playing an irreplaceable function in the nervous system. For this 
reason, MNDs such as amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), spinal 
muscular atrophy (SMA) and primary lateral sclerosis (PLS) are rapidly and irreversibly debilitating. 
Understanding the molecular mechanisms underlying MN diversity and susceptibility to degeneration is 
among the fundamental steps required to develop successful regenerative therapies in the future (Stifani, 
2014). 
 
1.2. ALS: Amyotrophic Lateral Sclerosis 
 
Amyotrophic Lateral Sclerosis (ALS) is a MND affecting both upper and lower motor neurons. It 
is characterized by weakness and muscular atrophy, leading to a progressive paralysis due to muscle 
denervation following motor neuron degeneration. The first symptoms can arise in the limbs (spinal form) 
or as dysarthria/dysphagia (bulbar form). After the focal initiation, symptoms spread to other regions over 
time and some evidence suggests that the spread may be mediated by non-cell autonomous propagation or 
“prion-like propagation” (Leblond et al., 2014). Progressive paralysis leads to death due to respiratory 
failure on average 3 years after the onset of the first symptoms, although a proportion of patients have a 
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slower disease course. The mean age of onset is approximately 55-60 years, incidence is 2 new cases per 
year every 100 000 people, with a slight male prevalence (M:F ratio 1,5:1) (Wijesekera and Leigh, 2009). 
Even though ALS has traditionally been considered a pathology affecting only MNs, recent 
findings in some patients have shown that sensory and spinocerebellar pathways may also be involved 
(Ferraiuolo et al., 2011). Moreover, neurons of the prefrontal and temporal cortex are also affected in 
ALS and degeneration of such neurons results in frontal executive dysfunction in many patients. Indeed, 
several observations have suggested that there is a link between ALS and Fronto Temporal Dementia 
(FTD). FTD is the second most common cause of early onset dementia, resulting in the degeneration of 
the frontal and temporal lobes of the brain. It occurs with an incidence of 3.5–4.1/100 000 per year in 
individuals under 65. Motor dysfunctions have been described in 15% of FTD patients and FTD is 
present in 15–18% of patients with ALS. There is also emerging evidence that these disorders share 
mutual pathological and genetic features, suggesting that they can be considered at the opposite ends of a 
same spectrum of diseases (Lattante et al., 2015; Robberecht and Philips, 2013) 
The majority of ALS cases are sporadic (sALS), although 5-10% of cases are familial (fALS), 
when the patient has a first or second-degree relative affected, and usually of autosomal dominant 
inheritance (Byrne et al., 2011). fALS is a genetically heterogeneous pathology with approximately 20 
disease-linked genes so far identified (Peters et al., 2015). Table 1 shows a comprehensive list of the 
genes whose mutations have been found in association with ALS.  
 Mutations in the gene encoding the enzyme [Cu/Zn] superoxide desmutase SOD1 are 
responsible for 20% of inherited ALS cases, while those in the RNA/DNA-binding proteins TDP-43 and 
FUS cause a small fraction (~5%) of FALS each. Hexanucleotide repeat expansions in C9ORF72 are the 
most common (40-50%) genetic cause of ALS and their identification established the molecular link 
between ALS and FTD. Several other genes have been identified as genetic causes of ALS and 
collectively today over 60% of fALS can be explained by known mutations. A small fraction of 
apparently sporadic patients present mutations in the genes known to cause fALS, thus revealing an 
unexpected clinico-pathological link between sALS and fALS.  
 
 
Gene % of fALS Locus Encoded Protein Inheritance 
Clinical 
phenotype 
Repeat expansion         
C9ORF72 40-50 9p21.3 C9ORF72 Dominant ALS, ALS+FTD 
ATXN2 1-2 12q24 Ataxin2 Dominant ALS; ALS+FTD; 
PMA 
Enzyme         
SOD1 20-25 21q22 SOD1 Dominant ALS, PMA 
Proteostasis         
OPTN 2-3 10p13 Optineurin Dominant ALS; ALS+FTD 
VCP 1-2 9 p13 VCP/p97 Dominant ALS; ALS+FTD; 
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Gene % of fALS Locus Encoded Protein Inheritance 
Clinical 
phenotype 
FTD 
SQSTM1 <1 5q35 p62/Sequestosome 1 Dominant ALS; ALS+FTD; 
FTD 
CHMP2B <1 3p11 CHMPB2 Dominant ALS; PMA;FTD 
FIG4 <1 6q21 Phosphatidylinositol 
3,5-bisphosphate 
5-phosphatase 
Dominant ALS;PLS 
UBQLN2 <1 Xp11 Ubiquilin2 X-linked dominant ALS, ALS+FTD 
ALS2 <1 2q33.1 Alsin Recessive ALS;PLS 
Cytoskeleton/ protein/lipid transport deficit     
PFN1 1 2 17p13 Profilin-1 Dominant ALS 
TUBA4A 1 2q35 Tubulin α4A Unknown ALS, ALS+FTD 
VAPB <1 20q13 VAPB Dominant ALS;PMA;PLS 
DCTN1 <1 2p13 Dynactin Dominant ALS 
NEFH <1 22q12.2 Neurofilament Heavy 
Chain 
Dominant ALS 
PRPH Unknown 12q13.2 Peripherin Sporadic ALS 
RNA processing         
TARDBP 4-5 1p36.2 TDP-43 Dominant ALS; 
ALS+FTD;FTD;  
FUS 4-5 16p11.2 FUS (FUS/TLS) Dominant ALS; ALS+FTD; 
FTD 
ANG 1-2 14q11.2 Angiogenin Dominant ALS, ALS+FTD 
TAF15 <1 17q11 TAF15 Unknown ALS 
EWSR1 <1 22q12.2 EWSR1 Unknown ALS 
hnRNPA1 <1 12q13 hnRNPA1 Dominant ALS+FTD 
hnRNPA2B1 <1 7p15 hnRNPA2/B1 Dominant ALS, ALS+FTD 
SEXT <1 9q34.13 Senataxin Dominant ALS 
Excitotoxicity           
DAO <1 12q24 D-amino-acid 
oxidase 
Dominant ALS 
Uncertain           
CREST <1 20q13.3 SS18L1 Unknown ALS 
MATR3 <1 5q31.2 Matrin3 Unknown ALS 
SIGMAR1 <1 9p13.3 SIGMAR1 Unknown ALS; ALS+FTD; 
FTD 
SPG11 <1 15q21.1 Spatascin Recessive ALS; HSP 
Table 1: Genetic causes of ALS. ALS: Amyotrophic Lateral Sclerosis; PMA: Primary Muscular Atrophy; PLS: 
Primary Lateral Sclerosis; FTD: Fronto Temporal Dementia; HSP: Hereditary Spastic Paraplegia (Peters et al., 
2015) (Robberecht and Philips, 2013) 
 
 Several studies have reported ALS/FTD cases with mutations in more than one ALS gene in 
the same individual, and the emerging idea is that the co-occurrence of mutations can modify the 
phenotype or influence the clinical features of the disease, such as age of onset and survival rate (Lattante 
et al., 2015). Since the C9ORF72 repeat expansion is the most common cause of fALS, most co-
1. Introduction 	  
	  	   	   	   4	  
occurrences have been observed to involve a C9ORF72 expansion alongside another mutation such as, 
for example, mutations in the TARDBP, OPTN, UBQLN2, VAPB, SOD1 and FUS genes (Leblond et al., 
2014). 
 Genetic factors can trigger disease pathogenesis through the alteration of one or more pathways 
converging on different aspects of cellular physiology. Cellular dysfunctions observed in ALS include, 
for example, oxidative stress, altered RNA metabolism, dysregulated endosome trafficking and cell 
signalling, glutamate excitotoxicity, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, 
altered protein degradation as well as cytoskeleton disorganization and impaired axonal trafficking 
(Robberecht and Philips, 2013) (Ferraiuolo et al., 2011). 
 The initiating events contributing to progressive MN loss observed in both sALS and fALS 
remain controversial and not fully determined. Given its complexity and multifactorial etiology, including 
both genetic and environmental factors, and the concomitant involvement of different intracellular 
pathways, ALS pathogenic mechanisms are likely to be linked, so that a defect in one cellular pathway 
will have a domino effect leading to multiple stresses on the cell. The clinical and pathological similarity 
between sporadic and familial forms suggests at least some common pathogenetic pathways. Therefore, 
unraveling the disease mechanisms of fALS-linked genes is important to understand the pathogenesis of 
the much more frequent sporadic forms (Robberecht and Philips, 2013).  
In the following sections, I will discuss in more detail some of the pathogenic mechanisms by 
which mutant proteins may induce disease.  
1.2.1. Pathogenic mechanisms underlying ALS. 
 
(i). Aggregate formation  
 
Different fALS-associated genes give rise to misfolded and aggregate-prone mutant proteins. 
Therefore, the presence of intracellular aggregates is a pathological hallmark of ALS, as for other 
neurodegenerative diseases. It is still unclear whether these aggregates are protective, by sequestering 
dangerous oligomeric species, or toxic. The toxic role of aggregates might be exerted either by causing 
“traffic jams” and inducing axonal transport impairment and mitochondria disorganization/dysfunction, 
or by interfering with the two major intracellular protein degradation pathways, the ubiquitin proteasome 
system (UPS) and autophagy (Navone et al., 2015). Deposits of misfolded mutant proteins may disturb 
the cellular degradative pathways on their own, via a gain of toxic function, or by sequestering functional 
proteins important for these processes. Moreover, intracellular inclusions formed by fALS-linked mutants 
proteins may sequester both their wild type counterparts and their endogenous binding partners, or even 
whole interactomes that could prove to be essential for neuronal physiology, leading to a loss of function 
of several pathways (Blokhuis et al., 2013).  
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SOD1 was the first gene and protein whose mutations were demonstrated to cause ALS. It is an 
enzyme composed of 153 amino acids and is involved in free radical scavenging. Mutant SOD1 is 
misfolded and targeted for degradation through ubiquitylation, however, it seems to escape this regulatory 
process in the cell. Mutant SOD1 accumulates as oligomers with a high propensity to form aggregates, 
thus leading to a cellular stress response. Eventually, cellular stress gives rise to axonal retraction and 
ultimately cell death (Robberecht and Philips, 2013) (see below).  
Mutations in TARDBP, which encodes the RNA and DNA-binding protein TDP43, are a rare 
cause of dominant fALS. This gene was investigated as a candidate gene for ALS because in most cases 
of sALS, fALS, and FTD the hyperphosphorylated, cleaved form of TDP-43 has been shown to 
accumulate diffusely in the cytoplasm of neurons and glia, where it assembles into round and thread-like 
inclusions. Under physiological conditions, TDP43 is localized in the nucleus, where it is involved in 
different aspects of RNA processing. Upon stress, it leaves the nucleus and accumulates in stress granules 
in the cytoplasm. If stress resolves, TDP43 is released from these sites and re-enters the nucleus. 
Mutations favor TDP43 leaving the nucleus and its irreversible accumulation in stress granules. Other 
proteins may be sequestered in the TDP43 accumulations (Andersen and Al-Chalabi, 2011)  (Ince et al., 
2011). 
Mutant FUS, an RNA-processing protein that shares some similarities with TDP43, is also 
detected in diverse types of intracellular inclusions like mutant SOD1 and TDP-43. In contrast with TDP-
43 aggregates, the frequency of FUS-positive inclusion bodies in sALS is low (Robberecht and Philips, 
2013) (Peters et al., 2015). 
The most frequent ALS-associated gene is C9ORF72. This gene encodes a protein of 
approximately 54.3 kDa (481 amino acids) whose function remains unknown, but recent studies suggest 
that it is structurally related to a GDP/GTP exchange factor  (GEF) that activates Rab-GTPases and that 
may be important for endosomal trafficking (Peters et al., 2015). The genetic alteration consists in the 
expansion of a GGGGCC hexanucleotide repeat in an intronic region. Healthy controls have 2-20 repeats, 
while affected patients typically carry hundreds or thousands of repeats (Rohrer et al., 2015). The 
GGGGCC expansion produces both nuclear RNA foci and cytoplasmic protein inclusions generated by 
Repeat-Associated Non-ATG (RAN) translation from the expanded GGGGCC repeat (Ash et al., 2013). 
The mechanism underlying RAN translation is not completely understood, but probably relies on a 
particular conformational structure adopted by the expanded region (Zu et al., 2011). 
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Figure 1.1: Overview of events implicated in the pathogenesis of ALS. From (Robberecht and Philips, 2013). See 
text for a more detailed description. 
 
(ii). Failure of proteostasis 
 
As described in the previous section, the presence of cytoplasmic inclusions or protein aggregates 
in affected motor neurons is a pathological hallmark of ALS, suggesting that impairment of protein 
degradation plays a role in the disease process. Unlike mitotic cells, which are able to clear aggregates of 
intracellular proteins through their dilution or asymmetric distribution during cell division, postmitotic 
neurons rely on two major pathways of protein degradation for aggregate removal: the UPS and 
autophagy-associated lysosomal degradation (Navone et al., 2015).  
The UPS regulates the turnover of many proteins and eliminates the unfolded ones. During 
ubiquitination, ubiquitin is covalently bound to a lysine in the target protein. Other ubiquitin molecules 
are subsequently conjugated to the first one and polyubiquitinated proteins are recognized and brought to 
the proteasome, where they are degraded (Lehman, 2009). With this mechanism, one protein at a time is 
degraded.  
During autophagy, double membranes form vesicles called autophagosomes that surround 
cytoplasmic components and later on fuse with lysosomes, where degradation occurs. Although this 
pathway has long been considered as a non-selective process responsible for the bulk elimination of 
cytosolic material, it is now clear that selective autophagy can remove aggregated proteins, damaged 
organelles as well as big complexes (Navone et al., 2015). Molecular chaperones, the UPS and the 
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autophagy-lysosome system function together to monitor protein quality and protect cells from 
dysfunctional, misfolded or denatured proteins. The presence of ubiquitin, p62 (an autophagy receptor) 
and molecular chaperones in ALS aggregates implicates a role for all these three systems in ALS 
pathophysiology.  
 Evidences from fALS causative genes support the hypothesis of a dysfunctional proteostasis as 
a pathogenic mechanism in ALS. For example, mutant SOD1 seems to have toxic effects on the cellular 
degradation machinery, impairing both the proteasome and the autophagy pathways. Further evidence for 
a failure of ubiquitin-dependent protein degradation in ALS comes from the discovery of some fALS-
linked mutations affecting proteins that are directly involved in proteostasis. For example, ubiquilin 2 
(UBQLN2) delivers ubiquitylated proteins to the proteasomal degradation machinery and mutations in 
this gene cause X-linked fALS or fALS-FTD. Mutations in SQSTM1 (p62) were found in patients with 
fALS and in individuals with sALS, but this gene was originally linked to neurodegeneration due to its 
presence in ubiquitin-positive cytoplasmic aggregates of misfolded proteins. Other genes involved in 
protein degradation and associated with ALS are those that encode autophagy receptors, such as 
Optineurin, the ER-Associated Degradation (ERAD, see below) protein p97, the endosomal ESCRTIII-
complex subunit CHMP2B and the phosphatidylinositol 3,5-bisphosphate 5-phosphatase FIG4 
(Robberecht and Philips, 2013) (Navone et al., 2015). 
(iii). RNA processing 
 
Numerous ALS-linked proteins are directly or indirectly involved in RNA processing. The most 
common are TDP-43 and FUS, but other less common genes have been found (see Table 1). TDP-43 and 
FUS function in almost every aspect of DNA and RNA processing, including transcription, splicing, 
RNA transport, miRNA processing, and translation. The mutant, ALS-associated variant proteins are 
mislocalized to the cytoplasm, often leaving the nucleus entirely depleted of the affected protein. It is 
unclear whether the primary pathology is loss of function in the nucleus or an acquired cytotoxic effect of 
the mutant protein (Robberecht and Philips, 2013).  
The association of mutant C9ORF72 with ALS shows another aspect of altered RNA biology in 
ALS. In patients with C9ORF72 mutations, the expanded hexanucleotide repeat forms nuclear RNA foci 
in neurons in the frontal cortex and spinal cord (DeJesus-Hernandez et al., 2011). Both sense and 
antisense RNA transcripts are present in these intranuclear foci.  How repeat expansions in C9ORF72 
cause ALS remains to be elucidated.  One possibility is that they may cause abnormal recruitment of 
splice factors, thus resulting in aberrant splicing of a whole range of genes. Such mechanism is suggested 
by studies in myotonic dystrophy type 1, where RNA foci transcribed from CTG expansions sequester the 
transcriptional splice factor Musclebind-like 1 (MBNL-1), depleting the pool of the protein in the 
nucleus. Besides sequestering transcription factors, the expanded GGGGCC sequence and/or the foci 
might reduce expression of the normal C9ORF72 protein, with deleterious effects on MN viability  
(Robberecht and Philips, 2013) (Peters et al., 2015). Finally, the expansion may generate insoluble and 
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potentially toxic dipeptide repeat proteins (DPR) proteins through the previously mentioned RAN 
translation (Ash et al., 2013). 
(iv). Alterations in the secretory pathway and impairment of axonal transport 
 
Recent studies suggest that dysfunctions in protein traffic and axonal transport constitute a 
common denominator in neurodegenerative diseases, including MND. The secretory pathway consists in 
a series of subsequent steps that cells use to move proteins between different organelles and finally 
deliver them to their proper destination. It starts in the endoplasmic reticulum (ER), which is recognized 
as the site of synthesis and folding of secreted, membrane-bound, and some organelle-targeted proteins. It 
then moves to the Golgi apparatus, where proteins can be modified, and from where they are sorted from 
the Trans Golgi Network (TGN) to reach their final destination. As the secretory pathway involves 
different steps, alterations in any of the organelles involved may contribute to dysfunctions in the whole 
system. The correct function of this process is critical: the MN cell body is the primary site of metabolic 
function, and must continuously supply newly synthesized proteins to dendritic and axonal processes. In 
this context, a common feature of both fALS and sALS is Golgi fragmentation, meaning loss of the 
normal ribbon-like configuration, which is replaced by disconnected vesicular pattern. However, whether 
Golgi complex disorganization in sALS is an indicator of pathogenesis or rather a secondary consequence 
remains to be determined (Nassif et al., 2010). In addition to anterograde transport from the cell body to 
dendrites and the axon, retrograde transport in the opposite direction must also be considered. This 
process is essential for the degradation of misfolded or aggregated proteins, as the cell body is the 
primary site for degradative functions (Chevalier-Larsen and Holzbaur, 2006).  
Axonal pathology is a key feature of ALS and is thought to have a crucial role in the 
pathophysiology of the disease. Since MNs are highly polarized cells with long axons, active transport 
from cell center to cell periphery, and from the periphery back to the cell body, is required for delivery of 
essential components, such as RNA, proteins and organelles to their proper destinations and to maintain 
the overall metabolic balance of the cell. Golgi-derived vesicles travel along microtubules to reach their 
final destination. Mutations in the motors that drive axonal transport are clearly sufficient to cause MN 
degeneration. Patients with missense mutations in the microtubule motors (like dynein or kinesin) 
develop neuropathies. As previously noted, cells carrying mutant SOD1show defects in axonal transport 
that contribute to the pathology (Chevalier-Larsen and Holzbaur, 2006). Cytoskeletal architecture and 
dynamics have a major role in ALS pathogenesis, as shown by the identification of mutations in several 
cytoskeletal components such as in the neuronfilament heavy chain, α-tubulin and profilin-1, a protein 
essential for actin polimerization (Robberecht and Philips, 2013) (Smith et al., 2014). TDP43 could 
indirectly affect cytoskeletal dynamics, as it has a role in the processing of mRNA coding for 
intermediate filaments (Millecamps and Julien, 2013).   
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(v). ER stress response 
 
 As described earlier, neurodegenerative diseases like ALS are characterized by accumulation of 
misfolded proteins. This leads to ER stress and activation of the Unfolded Protein Response (UPR), a 
series of cellular reactions aiming at re-establishing homeostasis in the presence of perturbations that 
compromise the protein folding capacity of the ER. At first, UPR activation initiates a signaling pathway 
leading to a reduction of protein load in the ER through a general inhibition of protein translation. 
Secondly, the folding capacity of the organelle is increased by upregulating the production of chaperone 
proteins. Finally, there is an upregulation of the ERAD pathway (ER-Associated Degradation), a system 
involved in the degradation of misfolded ER proteins via their retrotranslocation to the cytosol and 
delivery to the proteasome. Should these mechanisms fail, chronic ER stress will lead to irreversible 
alterations of the organelle and eventually trigger apoptosis (Hetz and Mollereau, 2014) (Ron and Walter, 
2007). 
 Three different UPR transducers have been identified, which are devoted to sensing the presence 
of abnormal amounts of unfolded proteins and activating downstream pathways: IRE1 (Inositol Requiring 
enzyme1), ATF6 (Activating Transcription Factor 6) and PERK (Protein kinase RNA-like Endoplasmic 
Reticulum Kinase) (Ron and Walter, 2007). 
 Recent studies suggest that cellular toxicity caused by UPR could be a relevant pathogenic 
mechanism in ALS. Both in sALS and fALS the presence of ER stress has been detected: several UPR 
transducers are upregulated in spinal cords of sALS patients and of mouse models carrying mutations in 
SOD1, TDP43, VAPB, FUS and Ataxin2 (Matus et al., 2013). Additional evidence in favor of an 
involvement of this pathway came from detailed studies on mutant SOD1 mice: in this model, ER stress 
is a very early alteration that precedes axonal damage, as it is already detectable in vulnerable MNs at a 
presymptomatic stage (Saxena et al., 2009). Moreover, genetic and pharmacological modulations of UPR 
alter disease progression of fALS models. In mutant SOD1 mice, treatment with Salubrinal, an ER stress–
inhibitor drug, attenuates symptoms and delays progression, whereas chronic enhancement of ER stress 
promotes the disease (Saxena et al., 2009). Genetic inactivation of one PERK allele accelerates disease 
onset and progression in mutant SOD1 mice, highlighting a protective activity of PERK in fALS 
pathogenesis (Wang et al., 2011). In contrast, deficiency of XBP-1 (the effector of IRE1) in the nervous 
system increases life span and MNs survival of mutant SOD1 transgenic mice and concomitantly 
enhances autophagy and diminishes levels of SOD1 aggregation (Hetz et al., 2009). These data suggest 
that different UPR effectors could play distinct roles in the cellular responses to mutant SOD1 protein 
misfolding. 
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(vi). Mitochondrial Dysfunction 
 
Mitochondria are cellular compartments essential for energy production, maintenance of Ca2+ 
homeostasis and regulation of apoptosis.  In ALS, several alterations in the mitochondrial compartment 
have been observed.  
Analysis of biopsies from sALS and fALS patients shows that in skeletal muscle and MNs 
mitochondrial morphology and localization are altered. More evidence regarding mitochondrial 
dysfunctions came from the analysis of mutant SOD1 mice. In this model, mitochondrial vacuolation is 
already present in a presymptomatic stage, suggesting that this is an early event in ALS pathogenesis 
(Ferraiuolo et al., 2011). In the same model, defects in the activity of respiratory chain complexes have 
also been detected (Lin and Beal, 2006). In addition, in a motorneuronal cell line overexpressing mutant 
SOD1, the mitochondrial network was severely fragmented (Raimondi et al., 2006). Interestingly no 
effect on mitochondria was observed in epithelial cells similarly overexpressing mutant SOD1, 
highlighting the particular sensitivity of motor neurons to mutant SOD1.  
Even though SOD1 is a cytoplasmic protein, in affected tissues small amounts of the mutant can 
be recruited onto the external surface of the mitochondria and also be imported into the inter-membrane 
space (Lin and Beal, 2006). Alteration in mitochondrial axonal transport has also been reported, which 
could influence energy production at the synapse (Millecamps and Julien, 2013). Finally, as ER and 
mitochondria are involved together in the regulation of intracellular Ca2+ levels, an imbalance in the first 
compartment due to ER stress could indirectly damage also the second one (Ferraiuolo et al., 2011). 
 
1.3. ALS8  
 
ALS8 is a slow onset form of fALS caused by a mutation in the VAPB gene situated at genomic 
locus 20q13.3. The link with the VAPB gene was initially identified in a large Brazilian family with 
Portuguese ancestry. Four generations of affected patients were observed and the mutation consists in a 
transition from C to T in exon 2 of the VAPB gene, resulting in the substitution of a proline at position 56 
with a serine residue in the mature protein (P56S-VAPB). The same variation was subsequently observed 
in six other Brazilian families, all but one with Caucasian ancestry (the remaining one has an African 
background) (Nishimura et al., 2004). Linkage analysis suggested that the distribution of this mutation in 
the affected families is due to a founder effect that occurred 23 generations before and that its origin dates 
back to the mid 15th century in Portugal, from where it was brought to Brazil during the first colonial 
period (Nishimura et al., 2005). In Europe, only one German family with the VAPB mutation has been 
identified, which is affected by late onset SMA and other dominant MND. These patients’ haplotype is 
different from the Brazilian one, suggesting that this mutation is not linked to the Brazilian founder. 
Three additional mutations of VAPB have since been identified in fALS patients (Chen et al., 2010)  
(Kabashi et al., 2013) (van Blitterswijk et al., 2012), however, in these cases, the segregation of the 
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mutation with the disease has not been demonstrated. 
 In addition to its involvement in ALS8, the P56S-VAPB has been linked to two additional 
MNDs: typical severe ALS with rapid progression and late-onset SMA (Spinal Muscular Atrophy) 
(Nishimura et al., 2004). The latter is a neurodegenerative disease characterized by selective death of 
SpMNs, muscular atrophy and generalized weakness (Lunn and Wang, 2008). This observation highlights 
once more the relatedness of different MNDs, which are part of a more general spectrum of pathologies. 
1.3.1 The VAPB Protein 
 
VAPB belongs to the VAP [Vesicle-associated membrane protein (VAMP)- Associated Protein] 
protein family. The VAMP-associated protein of 33 kD (VAP- 33) was first identified in A. californica 
(Skehel et al., 1995). This protein is highly conserved in different species, with homologues in yeast 
(SCS2), fly (DVAP-33), mouse, rat and human (VAPA and VAPB) (Lev et al., 2008). The two isoforms 
VAPA and VAPB share a high sequence homology (63%), while VAPC is a splicing variant of VAPB, 
which includes the first 70 aminoacids of VAPB followed by a unique sequence of 29 residues.  
The VAPB protein has three structural domains: the first 150 residues constitute a MSP domain 
conserved between all VAP family members and so called because of its 22% homology with the 
C.Elegans Major Sperm Protein (Lev et al., 2008). The central region of the protein contains a helical 
structure and is predicted to form a coiled/coil protein-protein interaction motif; finally, a hydrophobic 
carboxy terminus acts as a membrane anchor and contains a GXXXG dimerization domain. Given the 
presence of the single transmembrane domain followed by the short C-terminal tail, VAPs are integral 
membrane proteins denominated ER-resident, tail-anchored proteins. Thanks to this sequence and the 
coiled/coil domain, VAPB can make homo and heterodimers (with VAPA) (Kim et al., 2010). Moreover, 
VAP proteins from different species have a highly conserved sequence of 16 aminoacids inside the MSP 
(the VAP consensus sequence) (see Fig. 1.2). This region is also involved in the process of VAPB 
dimerization. Importantly, the MSP domain contains several positively charged aminoacids essential for 
the binding to proteins carrying the FFAT domain, two phenylalanines in an acidic tract (the complete 
sequence is EFFDAXE, where X is any aminoacid) (Kanekura et al., 2006).  
VAPA and VAPB are both ubiquitously expressed, however their expression varies among 
different tissues (Teuling et al., 2007). They are localized in the ER, even though they do not perfectly 
localize to all regions of this cellular compartment, suggesting that they may play preferential roles in 
distinct functional areas of the ER (Gkogkas et al., 2008). 
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1.3.2. VAPB functions 
VAPs are considered to be adaptor proteins that recruit to the ER numerous and diverse 
interacting partners, which have in common the possession of a FFAT motif capable of binding to VAP's 
MSP domain. These proteins have been implicated in a variety of physiological functions, including 
membrane trafficking, lipid transport and metabolism, membrane contact site formation, Ca2+ 
homeostasis, ER-cytoskeleton interactions, participation in the unfolded protein response, 
neurotransmitter release and neurite extension (Lev et al., 2008). So far, no functions exclusive to VAPA 
or VAPB have been identified. 
Below, I will describe some of the functions of VAP proteins before analyzing the characteristics 
of the ALS-associated mutant VAPB. 
(i). ER stress response 
 
An important aspect of VAPB function is in the ER stress response, although a role of VAP 
proteins in the regulation of the UPR has not been well defined, yet. Among the three previously 
described UPR transducers, IRE1, ATF6, and PERK  (see section 1.2.1), both VAPA and VAPB can 
directly interact with ATF6. More specifically, VAPB has an inhibitory effect on this transducer: when 
VAPB levels rise in the cell, ATF6 signaling decreases, while VAPB downregulation is followed by an 
increase in ATF6-dependent transcription. Since increased VAPB levels alter membrane trafficking, this 
could indirectly influence ATF6 activity by modifying its mobility from ER to the Golgi, a necessary step 
for ATF6 activation (Gkogkas et al., 2008).  
 
 
 
Figure 1.2: Schematic structure of VAP proteins (adapted from Lev et al., 2008), showing MSP domain (with VAP 
consensus sequence), Coiled-Coil Domain and Transmembrane domain. The lower part compares the VAP 
consensus sequences and the dimerization motifs from different species to show that they are evolutionary 
conserved. 
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 VAPB has also been implicated in the IRE1 pathway: its overexpression activates UPR through 
this pathway, while its downregulation attenuates IRE1 signaling (Kanekura et al., 2006).  
In summary, VAP proteins could regulate the UPR either by facilitating its activation via the 
classical transmembrane kinase IRE1, or, in contrast, by negatively modulating the activity of the UPR-
related transcription factor ATF6. 
(ii) Lipid transport at ER-Golgi Membrane Contact Sites (MCS) 
 
Although VAP proteins have been implicated in many processes, perhaps the best documented 
function and the one most relevant to neurodegeneration is their role in recruiting lipid exchange proteins 
to the ER membrane (Peretti et al., 2008). This depends on VAPs' ability to interact with the FFAT motif 
of proteins able to sense, bind or transfer lipids; among these lipid transfer proteins (LTPs) are CERT 
(Ceramide Transfer Protein), OSBP (Oxysterol Binding Protein) and Nir2 (PI/PC transport protein) (Lev 
et al., 2008). The transfer of lipids is thought to occur at ER regions in close contact to the Golgi 
membrane, known as membrane contact sites (MCS). Indeed, VAPs have been implicated in the genesis 
of MCS between the ER and other organelles, including the plasma membrane, endosomes, the yeast 
vacuole and the trans-Golgi network (Raiborg et al., 2015b). 
CERT transports ceramide from the ER to the Golgi. Ceramide is the precursor for all 
sphingolipids (SL), a class of lipids containing a sphingoid base. After de novo synthesis on the ER, 
ceramide needs to be transported to the Golgi to be further metabolized. At least two pathways exist for 
ceramide transport: a vesicular and a non-vesicular one. Vesicular transport is thought to be the major 
pathway of ceramide delivery for the synthesis of Glucosyl Ceramide (GlcCer), the common precursor of 
Glycospingolipids (GSL). The non-vesicular pathway is predominantly used for Sphingomyelin (SM) 
biosynthesis and relies on CERT. SM is synthesized through the transfer of the phosphocholine head 
group of phosphatidylcholine (PC) to ceramide (ceramide+PCèSM+diacylglycerol), a reaction catalyzed 
by SM synthase 1 and 2 (SMS1 and 2) in the trans Golgi. The CERT molecule contains several structural 
domains and aminoacid motifs, as illustrated in Fig. 1.3b: the N-terminal pleckstrin homology (PH) 
domain (≈100 amino acids), the C-terminal Steroidogenic Acute Regulatory protein (StAR)-Related lipid 
Transfer (START) domain (≈230 amino acids) and the two phenylalanines (FF) in an acidic tract (FFAT) 
motif at the N-terminal side of the START domain.  
The START domain is responsible for ceramide transfer. The PH and FFAT domains are 
necessary for the correct targeting of CERT at MCS between ER and Golgi. The PH domain binds to 
phosphatidylinositol 4-monophosphate (PI4P), which is highly abundant in the Golgi, especially at the 
trans Golgi cisternae and at the TGN, while the FFAT motif binds to VAP proteins (Yamaji and Hanada, 
2015). 
 
1. Introduction 	  
	  	   	   	   14	  
 
Figure 1.3.: general representation of a LTP that shuttles lipids between two compartments. b: structure of CERT 
and OSBP that carry dual membrane tethering domains (PH domain and FFAT motif) and a lipid transfer domain. 
From  (Holthuis and Menon, 2014). 
 
 
 OSBP transports cholesterol from the ER to the Golgi and back transfers PI4P to the ER, where it 
is quickly hydrolyzed to phosphatidylinositol (PI) by the phosphatase Sac1. The energy provided by PI4P 
hydrolysis drives sterol transfer (Mesmin et al., 2013). Similarly to CERT, the structural organization of 
OSBP shows a N-terminal domain PH domain that binds to PI4P, as well as a central FFAT motif that 
interacts with VAP proteins and a C-terminal lipid transport domain called OSBP-related domain (ORD) 
(see Fig. 1.3b for a schematic representation). 
Phosphoinositides are a class of lipids generated by phosphorylation of the precursor 
Phosphatidylinositol (PI) and are concentrated at the cytosolic surface of membranes. Reversible 
phosphorylation of the PI inositol ring, performed by different kinases and phosphatases at positions 3, 4 
and 5 results in the generation of seven phosphoinositide species. Each of the seven phosphoinositides 
has a unique subcellular distribution with a predominant localization in a subset of membranes. This 
spatial restriction and steady-state levels are determined primarily by the concerted action of 
phosphoinositide kinases and phosphatases, whose localization is tightly controlled (Balla, 2013) (Di 
Paolo and De Camilli, 2006).  
PI4P is the predominant phosphoinositide in the Golgi complex and a deficiency of this lipid 
affects its structure and function. PI4P synthesis is catalyzed by the activity of different PI4K 
(phosphatidylinositol 4-kinase). Spatial restriction of PI4P to the Golgi complex is ensured by 
phosphatases, which removes the phosphate group of PI4P in locations other than the Golgi, to obtain PI. 
Very interestingly, the phosphatase Sac1 is localized in the ER and binds VAP proteins via their 
transmembrane domain, thus revealing an important role of the VAPs not only in lipid transport, but also 
in their metabolism (Fig. 1.4): indeed in Drosophila models, downregulation of either Sac1 or DVAP (the 
homologue of VAP proteins) increases levels of PI4P (Forrest et al., 2013). PI4P is known to function in 
the recruitment of cytosolic proteins onto TGN membranes (Di Paolo and De Camilli, 2006) and, as 
explained above, it is involved in tethering both CERT and OSBP at MCS between Golgi and ER thanks 
to the PH domain of these proteins.  
Finally, the last LTP is Nir2, which transfers PI from the ER to the Golgi and Phosphatidyl 
Choline (PC) from the Golgi to the ER. The transported PI is subsequently phosphorylated into PI4P, thus 
enhancing the recruitment of OSBP and CERT to the Golgi (Lev, 2010) (Fig. 1.5). 
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Figure 1.4: Schematic representation of PI4P transport from Golgi to ER and subsequent dephosphorylation by 
Sac1. 	  	  
In conclusion, LTPs work in a coordinate way at ER-Golgi MCS. Most likely, Nir2 exchanges 
PC in the Golgi with PI in the ER; next, PI is phosphorylated by PI4K, thus generating PI4P that recruits 
OSBP and CERT through their PH domain. This allows non-vesicular ceramide transport and subsequent 
production of SM and DAG. Moreover, lipid traffic between the ER and the Golgi mediated by LTP is 
tightly linked to the turnover of PI4P, present at different concentrations on both partner membranes, and 
its regulation involves the PI4P dephosphorylating enzyme Sac1. Silencing of both VAPA and B 
isoforms causes mislocalization of CERT, OSBP and Nir2 and an alteration in their lipid transport 
function. As a consequence, lipid composition in the Golgi membranes is altered. Since a correct lipid 
composition is essential for organelle homeostasis, and especially for vesicular transport, in VAP-
depleted cells both Golgi to plasma membrane and to endosome/lysosome transport and Golgi to ER 
transport are inhibited (Peretti et al., 2008). Nonetheless, the effects of the downregulation of the sole 
VAPB on lipid transport have not been elucidated yet. 
(iii). Role of the VAPs in other MCS 
 
MCS between ER and the mitochondrial outer membrane (MOM) occur in a region termed 
MAMs (mitochondrial associated membranes). These sites of close membrane apposition, that involve 
from 5 to 20% of the outer mitochondrial membrane, have been implicated in a variety of processes, 
including Ca2+ and phospholipid exchange, ATP production, autophagy, protein folding in the ER, 
mitochondrial biogenesis and transport and apoptosis (Stoica et al., 2014).  
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Figure	   1.5:	   Schematic	   representation	   of	   lipid	   transport	  mediated	   by	   LTP	   at	   ER-­‐Golgi	   MCS.	   Adapted	   from	  
(Peretti et al., 2008). 
 
 
Several studies have linked defective ER-mitochondria interaction to neurodegenerative diseases. 
A recent paper showed that VAPB interacts with the mitochondrial protein PTPIP51 (protein tyrosine 
phosphatase-interacting protein 51), thereby regulating ER-mitochondria association (Stoica et al., 2014) 
and loss of one of these two proteins is sufficient to alter calcium absorption and buffering by 
mitochondria (De Vos et al., 2012). Moreover, the expression of the ALS-linked protein TDP43 seems to 
influence this binding: the expression of either the wt of mutant TDP43 alters VAPB-PTPIP51 binding 
and MAM formation (Stoica et al., 2014). 
 Other important MCS are formed between ER and Late Endosomes (LE), where they have a role 
in cholesterol transfer, receptor dephosphorylation, endosome positioning and fission. Distinct types of 
contacts sites have been identified, which are mediated by different molecular bridges. VAPs proteins 
have been involved in triggering several of them (Raiborg et al., 2015b). They are for example involved 
in STARD3 (START domain-3) and STARD3NL (STARD3 N-terminal like)-dependent MCS formation. 
These proteins are localized on LE and carry a START domain, that can bind and transfer cholesterol, 
and the FFAT domain, that can bind both VAP isoforms and trigger MCS formation (Alpy et al., 2013). 
In another paper, authors showed that VAPs interacts with the LE cholesterol-binding protein ORP1L. In 
conditions of reduced levels of free cholesterol on LE membranes, ORP1L is not bound to this lipid and 
assumes a conformation that allows the interaction of its FFAT motif with VAPs localized on the ER 
(Rocha et al., 2009). Despite both STARD3/ STARD3NL and ORP1L can sense cholesterol levels, their 
direct role in cholesterol transfer has not been demonstrated. More likely, they sense levels of this lipid 
and trigger MCS formation where other machineries are responsible for cholesterol transfer (Raiborg et 
al., 2015b). Moreover, as better described in the neurite extension section, VAPs are involved in the 
formation of ER-LE contacts mediated by protrudin, a process that allows the loading of LE from ER to 
microtubules and their subsequent movement (Raiborg et al., 2015b).  
(iv) Early secretory pathway 
 
The role of VAPB in the early secretory pathway was first suggested by observations obtained 
using the model protein VSVG to study intracellular transport. While downregulation of both VAPs has 
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been shown to inhibit the transport of VSVG from the TGN to the plasma membrane (Peretti et al., 2008), 
upregulation of VAPB was reported to enhance its transport (Rao et al., 2012). More recently, it has been 
shown that VAPB binds the ER-Golgi trafficking protein YIFIA, which is predominantly localized in the 
ER-Golgi intermediate compartment (ERGIC) and recycles between the ER and the Golgi in 
hippocampal neurons (Kuijpers et al., 2013b). In this cellular model, VAPB–YIF1A interaction controls 
the shuttling of YIF1A between the ERGIC and the ER and plays an important role in early secretory 
events in neurons, promoting membrane trafficking and normal dendritic growth and morphology.  
(v) Neurite extension 
 
Neurons are highly specialized and polarized cells characterized by long protrusions. The 
molecular mechanisms that underlie neurite formation include both cytoskeletal remodeling and 
membrane trafficking. In particular, extension and maintenance of neuronal processes relies on the 
directional transport of membrane components, which are conveyed in a vectorial manner within the cell 
by a membrane recycling system, resulting in expansion of the neurite surface area.  
 Recently, several reports have highlighted the importance of protrudin as a key regulator of 
Rab11-dependent vesicular trafficking during neurite extension. The GTPase Rab11 regulates membrane 
recycling and is thought to contribute to neurite formation through modulation of directional membrane 
transport. Protrudin is an ER-resident protein containing a Rab11-binding domain (RBD), three 
hydrophobic domains (HP-1, HP-2, and HP-3), a FFAT domain, a coiled-coil domain, and a FYVE 
(Fab1, YOTB, Vac1, and EEA1) domain for the binding to phosphatidyl inositol 3-monophospate (PI3P). 
Due to its many binding sites, protrudin engages in complex relations with several proteins, including 
spastin, the molecular motor KIF5 (a member of the kinesin-1 family which mediates the microtubule-
dependent anterograde vesicular transport of neurons), RAB7, PI3P (Matsuzaki et al., 2011) and both 
VAP A and B proteins, thus playing key roles in several aspects of neuronal function. 
Two splicing isoforms of protrudin are known: the ubiquitous one, called protrudin-S, and a 
novel form generated by the inclusion of a mini exon in the mature protrudin mRNA near the FFAT 
domain (protrudin-L). The expression of the latter isoform is mostly restricted to the central nervous 
system, where it is present in neurons and astrocytes. In contrast, oligodendrocytes express only the S 
form. The insertion of a seven-aminoacid sequence in the L form promotes the association of protrudin 
with both VAPA and VAPB, thereby increasing the stimulatory effect of protrudin on polarized neurite 
extension (Ohnishi et al., 2014). It appears that VAP proteins are important to determine both the 
subcellular localization of protrudin and its ability to stimulate neurite outgrowth. In particular, 
downregulation of VAPA in PC12 (a cell line derived from rat pheocromocytoma) strongly inhibits 
neurite extension (Saita et al., 2009). 
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Figure 1.6: schematic representation of protrudin-dependent neurite extension. From (Raiborg et al., 2015a). 
 
 
The most recently proposed model suggests that the role of protrudin in neurite outgrowth is 
based on the promotion of contact sites formation between ER and late endosome (LE) through its 
interaction with RAB7 and PI3P. These contact sites mediate transfer of the microtubule motor kinesin 1 
from protrudin to the motor adaptor FYCO1 on LE. Kinesin-loaded LE can therefore move on 
microtubules. Repeated LE-ER contacts promote microtubule-dependent translocation of LE to the cell 
periphery and their subsequent fusion with the plasma membrane (Fig. 1.6) (Raiborg et al., 2015a).  
(vi). Paracrine role 
 
Experiments in model animals like Caenorabditis Elegans (where the VAP homologue is VPR-1) 
and Drosophila Melanogaster (where VAP is known as VAP33 or dVAP) provided evidence for a 
paracrine role of VAPB. In particular, the N-terminal MSP domain of VAP proteins has been reported to 
be cleaved from the transmembrane domain and function as a secreted ligand by binding to receptors of 
the ephrin axonal repellent system (Peters et al., 2015; Tsuda et al., 2008).  
Ephrine (Eph) receptors are a well-conserved family of tyrosine kinase receptors. Their 
physiological ligands are ephrines, which are bound to the extracellular leaflet of the plasma membrane. 
Besides being found on oocytes (where they were originally identified), some of these receptors (such as 
EphA4 and A7) are expressed in the nervous system and adult skeletal muscle. Eph receptors have been 
1. Introduction 	  
	  	   	   	   19	  
shown to function in regulating MNs survival in vitro in culture and influence proliferation/apoptosis in 
the central nervous system of mammals (Magal et al., 1996) (Ricard et al., 2006). Moreover, they appear 
to interact with glutamate-NMDA receptors (Dalva et al., 2000), which suggests a possible link with the 
excitotoxicity observed in ALS.  
Both Drosophila and nematode MSP are thought to be secreted in the extracellular environment 
and to compete with ephrins for receptor binding (Tsuda et al., 2008) The mechanism of cleavage and 
secretion of VAP protein MSP domain is still unknown: given its localization on the cytosolic face of the 
ER membrane opposite to the lumen of the secretory compartment, its mechanism of secretion must 
require a still unidentified pathway, possibly similar to the unconventional one followed by other 
proteins, such as the Nef protein of HIV and interleukin1β (Nickel, 2010). 
When Drosophila and Caenorabditis, which have only one VAP gene, do not produce the 
protein, they show strong destabilization of mitochondria networks in muscle cells, which reflects 
alterations in cytoskeletal organization as a consequence of altered signaling between neurons and muscle 
cells. Indeed, when dVAP is selectively expressed in neurons, animals show a normal phenotype, while 
this doesn’t happen when it is selectively expressed in muscles. In Drosophila, it has been demonstrated 
that the secreted vMSP domain interacts with two muscular receptors, Sax-3 Robo and CLR-Lar. Most 
likely, Robo facilitates binding of vMSP to Lar or Robo/Lar complexes, reducing Lar signaling to the 
Arp2/3 complex, which is necessary for actin polymerization (see Fig. 1.7 for a schematic representation 
of VAP paracrine function). Lack of this modulation by vMSP affects mitochondria morphology and 
distribution (Han et al., 2012). 
 
 
  
Figure 1.7: Schematic representation of VAPB-MSP domain secretion and its effects on muscle cells. From (Han et 
al., 2012). 	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Recently, an additional role of VAP has been observed in muscle metabolism. In C. elegans, 
VPR-1 causes triacylglycerol (TAG) accumulation in striated body wall muscle. Similarly, in VAPB KO 
mice, VAPB downregulation increases the resistance of muscle lipid stores to fasting-induced 
mobilization. Whether the putative metabolic changes in mouse muscle are due to secreted vMSPs is not 
yet clear (Han et al., 2013). 
1.3.3. Mutant P56S-VAPB 
 
The P56S mutation of VAPB is located in the VAP consensus sequence and involves a highly 
conserved proline residue (see Fig. 1.2). This substitution dramatically alters the MSP domain structure, 
which, in physiological conditions and based on crystallography data, appears to be arranged in a seven 
filament beta sheet domain, similarly to immunoglobulins. In particular, whereas the proline residue 
makes an unusual cis peptide bond necessary to maintain the characteristic loop of this region, the serine 
present in the mutant makes a conventional trans peptide bond, causing the disgregation of the MSP 
domain, which becomes insoluble and aggregate-prone (Shi et al., 2010). Despite these structural 
alterations, work from our laboratory has shown that mutant VAPB can still correctly insert into ER 
membranes (Fasana et al., 2010). However, loss of the correct folding induces metabolic instability of the 
protein (Genevini et al., 2014; Papiani et al., 2012), and alterations in the MSP domain compromise the 
ability to bind the FFAT sequence, thus preventing VAPB association with its physiological interactors 
(Kanekura et al., 2006)  (Teuling et al., 2007). Wt VAPs interact with the P56S mutant, so that both wt 
VAPB and, to a lesser extent, VAPA have been shown to become sequestered in intracellular cytoplasmic 
insoluble aggregates in P56S- expressing cells (Suzuki et al., 2009) (Teuling et al., 2007).   
Given the multiple functions in which VAP proteins are known to be involved, there are several 
ways by which mutant VAPB could trigger pathogenicity, as suggested by several experimental studies 
performed in different in vitro models. One possibility is that P56S-VAPB may interfere with protein 
trafficking and lipid homeostasis (see previous chapter on VAPB functions). In this regard, an important 
feature of P56S-expressing cells is Golgi fragmentation, in agreement with the notion that altered 
intracellular transport and lipid metabolism cause disassembly of the Golgi apparatus (Teuling et al., 
2007). 
As for the ER stress response, both UPR branches where VAPB is implicated appear to be 
altered: although the mutant protein can still bind ATF6, it has been shown to exert a stronger inhibitory 
effect compared to the wt protein (Gkogkas et al., 2008). Moreover, it looses its ability to activate IRE1 
(Suzuki et al., 2009). A general malfunctioning of VAPB-mediated UPR could lead to an accumulation of 
unfolded proteins in the ER, which could contribute to MNs death (Suzuki et al., 2009).  
Besides damage in the ER, ALS is characterized by alterations in mitochondria and calcium 
homeostasis, as described in a previous section. As recent data implicate VAPB in calcium uptake by 
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mitochondria (De Vos et al., 2012), an impairment of VAPB function could play a role in this aspect of 
the pathology. Another feature regarding mitochondria is their mobility. Mitochondria transport along 
axons is a vital process for neurons. In addition to producing ATP, these organelles are essential to 
maintain calcium concentration at the synaptic terminal, which is necessary for a correct vesicle 
exocytosis. Mitochondria are moved to the periphery by microtubule-mediated anterograde transport. On 
the outer mitochondrial membrane the integral membrane protein Miro-1 (mitochondrial Rho GTPase-1) 
binds the adaptor protein TRAK (trafficking kinesin protein-1) which, in turn, binds the motor protein 
kinesin-1, thus promoting the anterograde transport of the whole complex along microtubules. The 
presence of P56S-VAPB interferes with anterograde (but not retrograde) transport of mitochondria, 
reducing speed, movement frequency and persistence. These alterations could be the consequence of 
altered calcium homeostasis caused by the expression of the mutant (Morotz et al., 2012).  
Finally, regarding the paracrine function of VAPB, the P58S mutation of Drosophila VAP33 has 
been reported to cause a decrease in MSP-VAP secretion, thus interfering with neuron-muscle cross-talk 
at the neuromuscular junction. This mechanism could alter the target cell and, synergistically with the cell 
autonomous damage of P58S, could contribute to ALS pathology (Tsuda et al., 2008). Indeed, the 
reduction in vMSP secretion and consequent alteration in Robo/Lar signaling causes defects in muscle 
cells of P58S-carrying organisms. 
Characteristics of P56S-generated aggregates 
 
Like in many neurodegenerative diseases, which share the common feature of accumulating 
mutant proteins, P56S-VAPB transiently expressed in a variety of cultured cells forms perinuclear 
cytoplasmic inclusions that can be observed at the optical microscope. Ultrastructural analysis, however, 
revealed dramatic differences between P56S-VAPB inclusions and other inclusion bodies linked to 
neurodegenerative disorders. In particular, mutant VAPB inclusions correspond to profoundly 
restructured ER domains and not to a cytosolic protein aggregate, as is generally the case. They 
correspond to a novel form of OSER (Organized Smooth ER), consisting of two or three juxtaposed ER 
cisternae separated by a 30 nm electron-dense cytosolic layer (see Fig. 1.7). The electron-dense layer 
between two tubules is in continuity with the cytoplasm and is enriched in mutant VAPB. Pairing of two 
cisternae is most likely mediated by trans interaction of VAPB mutated cytosolic domains (Fasana et al., 
2010) (Papiani et al., 2012). Immunofluorescence studies revealed that many ER markers are present 
within the inclusions, while FRAP experiments showed that these aggregates are in continuity with the 
rest of the ER (Fasana et al., 2010). Finally, formation, clustering and localization of P56S-VAPB 
inclusions to the juxtanuclear region was shown not to depend on the microtubule cytoskeleton, in 
contrast with inclusions observed in other neurodegenerative diseases (Papiani et al., 2012).  
Recent evidence from our laboratory showed that in newly formed inclusions, P56S-VAPB is 
ubiquitinated and that mutant protein is cleared from cells faster than the wt one. Using drugs that 
specifically inhibit either the proteasome or autophagy (MG132 and 3-Methyladenine, respectively), we 
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demonstrated that P56S-VAPB degradation is blocked with the first, but not the second treatment, 
indicating that mutant VAPB is eliminated by the proteasome. Moreover, in immunofluorescence 
experiments no colocalization could be detected between P56S inclusions and the autophagic receptor 
p62, a protein that binds ubiquitinated proteins and selectively shuttles them to the nascent 
autophagosome for subsequent degradation (Papiani et al., 2012). This result was unexpected, since the 
elimination of inclusion bodies observed in other neurodegenerative diseases  (like Huntington and 
Parkinson) is usually autophagy-dependent (Ravikumar et al., 2002).  
Given that proteasome-mediated degradation proceeds by eliminating one protein molecule at a 
time, P56S-VAPB has to be extracted from aggregates where it is tightly packed before being eliminated. 
Since it is an ER transmembrane protein, its delivery to the proteasome must involve extraction, not only 
from the aggregate, but also from the ER membrane. For this reason, the involvement of ERAD (ER 
Associated Degradation) in the degradation of mutant VAPB was investigated. An important ERAD 
factor is the AAA-ATPase p97/VCP, which utilizes the energy derived from ATP hydrolysis to extract 
substrates from the ER to the cytosol. By using a dominant negative mutant of p97 we demonstrated that 
this protein has an important role in P56S degradation. p97 could be involved in the extraction of VAP 
proteins from the lipid bilayer and at the same time dissolve protein-protein interactions responsible for 
the aggregation (Papiani et al., 2012). 
 
 
 
 
Figure 1.8. P56S-VAPB aggregates. A: immunofluorescence image showing intracellular localization of P56S-
VAPB. Blue: DAPI, green: P56S-VAPB inclusions, gray: phase contrast. B: electron microscopy showing altered 
ER structure following P56S-VAPB expression. C: electron microscopy at higher magnification Asterisks indicate 
ER cisternae, arrowheads ribosomes. Scale bars: A: 10 µm, B: 500 nm, C: 200 nm. Adapted from (Papiani et al., 
2012).  
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1.3.4.   Possible pathogenic mechanisms of mutant VAPB 
 
 ALS8 is a dominantly inherited pathology: the presence of only one mutated allele is sufficient to 
trigger the development of the disease. In general, dominant inheritance can be explained by either a gain 
or loss of function of the mutant protein, even though intermediate situations where both mechanisms 
contribute are possible. In the gain of function hypothesis, the mutant protein has an enhanced or a 
completely new function that is toxic for cells, while in the loss of function situation, levels of the normal 
protein are not sufficient to support cellular homeostasis. This might be due either to pure 
haploinsufficiency, when the mutant protein is completely inert, or dominant negative activity of the 
altered protein that binds and sequesters the native one, thus further reducing its levels inside the cell. 
 The pathogenic mechanism of P56S-VAPB is still unclear, and in the literature there is evidence 
supporting both a gain and a loss of function hypothesis. 
Supporting the first hypothesis, as previously described, transient in vitro transfection of the 
mutant protein has been shown to alter several cellular pathways in which VAPB is involved. However, 
several studies with mouse models question whether unregulated P56S-VAPB expression and aggregate 
formation are able to trigger ALS in vivo. As a matter of fact, even though P56S-VAPB expressed in vivo 
forms cytoplasmic aggregates similar to those observed in vitro, several studies with transgenic mice 
models failed to show defects in motor performances (Kuijpers et al., 2013a) (Qiu et al., 2013) (Tudor et 
al., 2010). Only one model, which specifically overexpressed P56S-VAPB in neurons, with a 7-fold 
increase compared to endogenous VAPB (the highest so far described in mice), showed motor defects in 
aged mice (Aliaga et al., 2013), along with an increase in UPR activation and selective degeneration of 
cortico-spinal MNs. A more in depth analysis of the above cited works suggests that a dose dependent 
mechanism is probably responsible for the development of motor abnormalities following P56S-VAPB 
overexpression. For example, Tudor, whose mutant mouse had a moderate overexpression of the 
transgenic protein in the nervous system, only saw a subtle cytoplasmic TDP-43 accumulation in old 
mice. In contrast, Qiu, whose model only had a 2-fold ubiquitous overexpression of P56S-VAPB, failed 
to see any difference compared to wt mice, leading the authors to suggest that MNs can tolerate the 
presence of mutant VAPB aggregates without degenerating.  
 Taken together, the studies described above indicate that, at least in the mouse, toxicity of mutant 
VAPB cannot, by itself, explain its dominant inheritance. Most of the mouse models carrying the 
mutation showed visible inclusions however, they did not develop motor deficits, a sign that MNs can 
cope with the presence of the aggregates. It is also a matter of debate whether ALS8 patients have 
inclusions. Since there are no autoptic data, the closest available model are iPSCs differentiated into MNs 
derived from affected patients (Mitne-Neto et al., 2011). These cells do not develop visible inclusions, 
however, they show reduced VAPB levels, up to half compared to controls.  
 To analyze mechanisms alternative to aggregate toxicity, it is useful to compare the results of two 
recent studies, one reporting on either heterozygous or homozygous VAPB-knock-out mice (Kabashi et 
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al., 2013), the other on a knock-in mouse that expresses the mutant protein in its correct genetic locus, 
and has physiological levels of the mutant protein (Larroquette et al., 2015). Both these models showed 
mild motor defect, which were slightly more severe in the knock-in model. These results suggest that the 
loss-of-function caused by the lack of the product of one VAPB allele may be aggravated by the 
production of the mutant protein. Since the aggregates themselves do not appear to be toxic (as discussed 
above), the effect of the mutant protein could be due to a dominant negative effect; indeed wt VAPB and, 
to a lesser extent, VAPA are recruited into P56S-VAPB-generated inclusions (Teuling et al., 2007). The 
dominant negative effect would become harmful only in the context of already reduced levels of wt 
VAPB. It should, however, be kept in mind, that P56S-VAPB is unstable, so that one would not expect it 
to accumulate in neurons that express it at normal levels. Therefore, the difference in the knock-in and 
knock-out model may simply reflect differences in the genetic background of the mice used in these 
studies.  
In summary, the mouse model studies suggest that the dominant inheritance of VAPB cannot be 
explained solely by a toxic effect of the aggregates, as pathological effects in transgenic mice with two 
normal VAPB alleles were observed only under conditions of unphysiological overexpression of the 
mutant protein. In contrast, normal levels of expression of the mutant in a genetic background with only 
one normal allele did produce mild motor deficit, suggesting that at least partial loss of VAPB function is 
required for pathogenicity.  
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2. Aims of the thesis 
 
 ALS is a fatal neurodegenerative disease characterized by degeneration of MNs leading to 
progressive paralysis and eventually death due to respiratory failure. So far, no effective treatments are 
available for this devastating disease. Interestingly, genetic forms of ALS show the same pathological 
alterations observed in the most frequent sporadic cases. For this reason, studying the role of single 
disease causing mutations is important to gain insight into the pathophysiological events that lead to 
disease development. 
VAPB is one of the less investigated genes linked to fALS. However, because of the reduction of 
VAPB levels observed also in sporadic ALS, elucidating its pathogenic mechanism may be important not 
only for the rare fALS form that it underlies, but also for a more general understanding of the pathogenic 
factors triggering sALS 
 As described in the introduction, the cellular and molecular mechanisms underlying pathogenicity 
of mutant VAPB are still poorly understood. It is still unclear whether P56S-VAPB-generated inclusions 
exert a direct toxic function or whether reduced levels of the wt protein are sufficient to trigger the 
disease. An intermediate situation, where both mechanisms contribute to ALS development, could also be 
possible. 
 The aim of my thesis is to analyze the contribution of mutant VAPB gain or loss of function in 
the development of ALS. To reach this goal, I investigated whether P56S-VAPB could interfere with 
physiological protein degradation and trafficking pathways and, in parallel, whether downregulation of wt 
VAPB produced detrimental effects on motorneuronal cell viability. To address these questions, I used 
two complementary experimental approaches. First, because previous cellular studies were carried out 
with heavily overexpressed mutant VAPB, I used epithelial and motorneuronal cellular models 
expressing only moderate levels of the protein to analyze a possible toxic action in a context more closely 
resembling the diseased organism. Second, I developed stable VAPB-downregulated motorneuronal cell 
lines to examine if partial or near complete lack of this protein could have any deleterious effect. The cell 
line I used (NSC34) was derived from primary murine MN and is the best available one to study 
motorneuronal diseases.   
 By integrating the results obtained with the two approaches I expect to broaden our knowledge on 
mutant VAPB pathogenic mechanisms. 
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3. Materials and Methods 
 
3.1. Plasmid construction 
3.1.1. Bacterial transformation with plasmid DNA 
The following media were used to grow bacteria: 
 
LB (500 ml autoclaved) - 
brought to pH 7.2 with 
NaOH 
 
SOB (1L autoclaved) 
brought to pH 7.2 
with NaOH 
 
FSB (sterile filtered) 
brought to pH 6.8 with 0.1 N HCl 
 
Tryptone   5g 
 
Tryptone         20 g 
 
MnCl2                                45 mM 
 
Yeast extract   2.5g 
 
Yeast extract   5 g 
 
CaCl2                                  10 mM 
 
NaCl    5g 
 
NaCl   0.5 g 
 
KCl                                     100 mM 
 
+Agar for petri dish  7,5g 
 
KCl            0.18 g  
 
Glycerol                                10% 
 
  Hexamine cobalt chloride 3 mM 
 
  Potassium acetate            10 mM 
 
 
 To prepare bacteria competent to incorporate exogenous DNA, the method developed by 
(Hanahan, 1983) was followed with slight modifications.  
 The DH5α strain of E.Coli was used since it is optimized to amplify plasmid DNA. Two colonies 
of non competent bacteria grown overnight (o/n) at 37°C on a LB+agar petri dish were inoculated in 100 
ml SOB medium supplemented with 20 mM MgSO4. The culture was grown at 37°C with shaking until it 
reached 0,1 OD (optical density) at 600 nm (this corresponds to the beginning of the log phase of 
growth). The culture was split into two 50 ml tubes and centrifuged for 10 minutes at 4000 rpm at 4°C, 
then each pellet was resuspended in 20 ml cold FSB (see the table above). After 10 minutes of incubation 
on ice, the bacteria were centrifuged again and resuspended in 4 ml of cold FSB. After adding 140 μl of 
dimethylsulfoxide (DMSO), the bacterial suspension was incubated for 15 minutes on ice. Finally, after 
adding an additional 140 μl DMSO aliquot, the bacteria were transferred into single-use cryogenic vials, 
immediately frozen in liquid nitrogen, and stored at -80° until use. 
 Competent bacteria were thawed and kept on ice for 10 minutes. In the meantime, 2-20 ng of 
plasmid DNA were diluted in 10 μl of water in transformation tubes. 100 μl of bacteria were added to the 
DNA solution and left on ice for 30 minutes. Next, they were subjected to a heat shock step for 90 
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seconds at 42°C, thus allowing the DNA to enter the cells. After a quick cooling step on ice, 800 μl of 
SOC medium (SOB supplemented with 20mM glucose and 10 mM MgCl2) were added and the bacteria 
were incubated for 1h at 37°C with shaking to allow recovery. Finally, they were plated on a LB+agar 
petri dish supplemented with the appropriate selection antibiotic and allowed to grow o/n (overnight) at 
37°C.  
3.1.2. DNA extraction (MINI and MIDI preparation) 
 Following transformation, MINI preparations were used to screen bacterial colonies carrying the 
plasmid of interest and MIDI preps to obtain DNA for sequencing and transfection. While MIDIs were 
performed using the Plasmid MIDI kit from Qiagen, MINIs were prepared according to the procedure 
described in (Sambrook and Russel, 2001), as outlined below.  
 Briefly, each colony was inoculated into 2 ml of LB supplemented with the appropriate selection 
antibiotic and incubated o/n at 37°C with shaking. 500 μl of the resulting bacterial suspension was stored 
at 4°C, while the rest was subjected to DNA purification. The solution was centrifuged for 2 minutes at 
12 000 rpm at 4°C and the bacterial pellet resuspended in 100 μl of resuspension buffer (50 mM Tris-HCl 
pH 8.0, 10 mM EDTA, 100 μg/ml RNase A). 200 μl of lysis buffer (1% SDS, 0,2 N NaOH) was added to 
lyse cells and denature DNA. After briefly shacking the sample, 150 μl of neutralization buffer (3 M K+ 
acetate, pH 5.5) was added to neutralize the effects of the lysis buffer and to generate a K+-SDS 
precipitate. Under these conditions, the small plasmid DNA is renatured, while the large chromosomal 
DNA co-precipitates with the K+-SDS. After a 5 minute incubation on ice, the sample was centrifuged at 
13 000 rpm at 4°C for 15 minutes to eliminate genomic DNA and cell debris. Two volumes of 100% 
ethanol were added to the supernatant to precipitate plasmid DNA. After a 30 min incubation at RT, the 
sample was centrifuged at 13 000 rpm at 4°C for 15 minutes and the DNA pellet was washed with 30 μl 
of 70% ethanol and centrifuged again for 10 minutes. Once dried, the DNA was resuspended in water and 
stored at -20°C. 
3.1.3. Construction of recombinant plasmids  
(i). Plasmid for siRNA silencing 	  
 shRNAs are small RNA molecules composed of a sense and antisense sequences separated by an 
hairpin loop. Following transcription, sense and antisense (red and blue in Fig. 3.1) anneal, thus forming a 
tight hairpin turn. shRNAs are processed by the cellular machinery into mature and active siRNAs 
(Brummelkamp et al., 2002).  
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Figure 3.1: structure of the two oligonucleotides used for preparation of pSuper.neo.GFP plasmid targeting VAPB 
 
 To create stable cell lines silenced for VAPB expression, I used the pSuper.neo.gfp vector 
(OligoEngine). As shown in Fig. 3.2, this plasmid carries the sequences for expression of ampicillin for 
bacterial resistance, neomycin (G418) for mammalian cells resistance and soluble EGFP. The restriction 
sites used for insertion of the shRNA sequence (BglII and HindIII) are indicated. To drive the expression 
of endogenous the shRNA, the vector uses the H1 RNA polymerase III promoter (Brummelkamp et al., 
2002).  
 The two DNA oligonucleotides targeting VAPB mRNA (shown in Fig. 3.1) were obtained from 
Sigma (PAGE purification) and were annealed to obtain a double stranded DNA. Briefly, the two 
oligonucleotides (500 pmol each) were mixed in 50 μl of TE buffer (10 mM TrisHCl, pH 7.5, 1 mM 
EDTA), heated for 5 minutes at 95°C, and allowed to cool to room temperature (RT) on the bench. Next, 
the annealed oligonucleotides were 5’ phosphorylated with Polynucleotide Kinase (NEB). In parallel, the 
vector was double digested with BglII and HindIII (NEB), purified (Nucleospin Extract II, Macherey-
Nagel), de-phosphorylated with Shrimp Alkaline Phospatase (NEB) and purified again. The annealed 
oligos were ligated into the digested dephosphorylated pSuper.neo.GFP, using T4 DNA ligase (Promega), 
and the ligation mixture was used to transform competent E.Coli DH5α. Plasmid DNA miniprepes were 
prepared from antibiotic-resistant colonies. 
 The insertion of the annealed oligo into the p.Super.neo.GFP disrupts the BglII restriction site. 
Therefore, the loss of this restriction site was used to screen the purified DNA by BglII digestion. Positive 
clones were expanded, and the plasmid DNA was sequenced by MWG Eurofins. 
(ii) Other plasmids 	  
 pCINeoHACD3δ was used to analyze proteasome function and was generously provided by A.M. 
Weissman (National Institutes of Health, Bethesda, MD). pCDM8.1-ts045VSVG-EGFP was used to 
study protein transport and was a kind gift of J. Lippincott-Schwartz (National Institutes of Health, 
Bethesda, MD. The pTre-Tight vectors (Clontech), coding either for myc-wt-VAPB or myc-P56S-VAPB 
were used to generate stable inducible NSC34 Tet-Off cell lines and were already available in our 
laboratory (Fasana et al., 2010). pEGFP-N1 (Clontech) was cotransfected with pCINeoHACD3δ and 
used to check transfection efficiency; pTK-hygro (Clonthech) was cotransfected with pTre-Tight vectors 
and used to grant hygromycin resistance to mammalian cells.  
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Figure 3.2: pSuper.neo.GFP (OligoEngine) sequence map. 
 
3.2. Cell Culture 
3.2.1. Hela Tet-Off cell lines 
 HeLa (an epithelial cell line derived from cervical cancer) Tet-Off cell lines inducibly expressing 
a myc-tagged version of either wild type-VAPB or mutant P56S-VAPB had been previously generated in 
the laboratory (Fasana et al., 2010). Thanks to the stable insertion of the Tet-Off plasmid (Clontech), 
these cells express the transgenic product only in the absence of doxycycline (Dox) (see Fig. 3.3).  
 Cells were grown in DMEM supplemented with 10% FBS Tet-free (purchased from Clontech or 
Euroclone), 1% Penicillin/Streptomycin, 1% L-glutamine at 37°C with 5% CO2. At the first passage after 
thawing, 100 μg/ml G418 and 100 μg/ml hygromycin were added to the culture medium to maintain 
stable insertion of the Tet-Off and pTreTight plasmid respectively. Cells were grown in the presence of 
500 ng/ml Dox to repress the expression of the transgenic product. To induce expression of the trans-
gene, Dox was removed from the medium and cells were grown for 6 days in the absence of the antibiotic 
(Papiani et al., 2012).  
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Figure 3.3: Schematic representation of Tet-Off system. In absence of Dox in culture medium, TetR is free to bind 
to TRE and activate the transcription of the downstream transgene.  
3.2.2. NSC34 cells 
 Neuroblastoma Spinal Cord (NSC34) is a mouse cell line created by fusion of a neuroblastoma 
line with spinal cord primary motor neurons, and currently represents the best characterized available cell 
line with motorneuronal characteristics. These cells express ChAT (Choline Acetyl Transferase), the key 
enzyme for acetylcholine synthesis, make neurite-like protrusions, support action potentials and express 
neurofilament proteins. Moreover, NSC34 cells make contacts with co-cultured myotubes, and induce 
contraction and clustering of acetylcholine receptors (Cashman et al., 1992). 
NSC34 were maintained in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 
1% L-glutamine and 1% Na+ pyruvate at 37°C with 5% CO2.  
These cells will be called NSC34 wild-type (wt). 
Differentiation of NSC34 	  
 For differentiation, cells were plated onto Matrigel (BD Bioscience)-coated plates and grown 
with differentiating media, consisting of DMEM/F12 supplemented with 1% FBS, 1% 
penicillin/streptomycin, 1% L-glutamine, 1% Na+ Pyruvate, 1% Non Essential Amino Acids (NEAA) and 
1 μg/ml all-trans retinoic acid (Sigma, 10 mg/ml stock solution diluted in ethanol) (Maier et al., 2013). 
Since retinoic acid is unstable in culture, the media was changed every 2 days.  Unless otherwise stated, 
cells were grown in differentiation medium for six days and then either fixed for immunofluorescence or 
collected to make a cell lysate and analyzed by Western blot. Neurite length of the cells at various stages 
of differentiation was determined on images of tubulin-stained cells acquired with a 10x magnification 
lens (see section on microscopy and legend to Fig 4.17 for details) 
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3.2.3. NSC34 tTA40 
 NSC34 tTA40 are an NSC34-derived stable cell line that expresses TetR (see Fig 3.3). This 
allows them to inducibly express a transgenic protein, encoded in a pTre-Tight plasmid, after Dox 
removal. These cells were generated in the laboratory of Dr. Cantoni (Babetto et al., 2005) and 
maintained in DMEM supplemented with 10% FBS, 1% P/S, 1% L-Glutamine, 1% Na+ pyruvate and 250 
μg/ml G418. 
 
3.3. Transfection 
3.3.1. Transient siRNA transfection 
  The transfecting reagent (Lipofectamine) and siRNAs were obtained from Invitrogen. Cells were 
plated in penicillin/streptomycin-depleted media 24 h before silencing in 12 multiwell (mw) plates and 
allowed to grow to 40% confluence. Prior to the experiment, the medium was removed and 800 μl of 
fresh medium was added. For each well, two solutions were prepared: the first one containing the 
appropriate siRNA mixture, the other one 2 μl of Lipofectamine; both were diluted in 100 μl of Optimem. 
After mixing, the siRNA solution was added to the one containing the Lipofectamine. This mixture was 
stored at RT for 20 minutes and finally added to cells. The final concentration of siRNAs in the well was 
10nM. After 6h, the medium was removed, the cells were washed and returned to the incubator with 
complete, penicillin/streptomycin containing media. 
 The following siRNAs, retrieved from the Invitrogen catalogue, were used to downregulate 
VAPB (for each oligonucleotide pair, only the sense strand is shown):  
siRNA 1 (MSS285791) 5’ UGGCCCUGGUGGUUCUGUUCUUUAU 3’ 
siRNA 2 (MSS285792) 5’ CAUUAUAGGGAAGAUUGCCUUGUAG 3’ 
siRNA 3 (MSS244288) 5’ GCAGCUCAAGGAAGAAGACGGACUU 3’ 
3.3.2. Transient DNA transfection 
 All transfections were performed with JetPEI (Polyplus Transfection). Hela and NSC34 tTA40 
cells were transfected according to the manufacturer's instructions. Briefly, cells were plated 24h before 
transfection in 6 mw plates to allow growth to 50% confluence. Prior to transfection, the medium was 
changed to remove cell debris. For each well, two solutions were prepared: the first one containing 3 μg 
of DNA, the second one 6 μl of JetPEI; both were diluted in 100 μl of 150 mM NaCl. After mixing, the 
JetPEI solution was added to the one containing the DNA. This mixture was stored at RT for 20 minutes 
and then added to cells.  
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 The protocol described above for Hela and NSC34 tTA40 cell lines lead to massive death of wt 
NSC34 cells. Therefore, the manufacturer’s protocol was adapted for the latter cell line and both the 
amount of DNA and JetPEI used were reduced: for transfection in 12mw plates, the reaction was 
performed with 750 ng of DNA and 1,5 μl of JetPEI. 
3.3.3. Stable DNA transfection and selection of cell lines 
 To obtain stable VAPB downregulated cell lines, wt NSC34 were transfected with either the 
empty pSuper.neo.GFP vector or the one coding for a VAPB-targeted shRNA (see section 3.1.3) 
designed after choosing the target sequence with transient VAPB downregulation with siRNAs (see Fig. 
4.11).  
 To generate NSC34 Tet-Off VAPB clones, NSC34 tTA40 cells were co-transfected with pTK-
hygro and pTre-tight vectors coding either for myc-wt-VAPB or myc-P56S-VAPB. The transfection was 
performed in presence of Dox to inhibit the expression of the transgene.  
One day after transfection, cells were diluted 1:10 and plated in 10 cm petri dish. After two more 
days, selection was initiated on the basis of growth in 500 μg/ml G418 for the pSuper vectors and 150 
μg/ml hygromycin for pTre-tight plasmids. The media were changed every 3-4 days to remove dead cells 
and maintain antibiotic concentration.  
 After 3-4 weeks visible colonies were collected with cloning cylinders (Sigma), amplified and 
frozen. One aliquot of each clone was used for screening by western blot analysis. VAPB downregulated 
cell lines were screened by assessing the expression levels of the endogenous VAPB. Tet-Off clones were 
induced to express the transgene by growth in the absence of Dox for 4–5 days. Enhancement of gene 
expression was obtained by addition of 10 mM Na+Butyrate for 12 h. Positive clones were identified by 
the presence of the myc-VAPB band on Western Blots. 
 
3.4. Drug treatments and starvation 	  
 Lactacystine and Torin 1 were from Cayman Chemical; MG132 was from Calbiochem. Other 
drugs were from Sigma. 3-Methyladenine (3-MA) and Cycloheximide (CHX) were dissolved in water 
and used at a final concentration of 10 mM and 50 mg/ml, respectively. Na+ Butyrate was dissolved in 
complete medium and used at 10 mM final concentration. The following drugs were dissolved in DMSO 
and used at the final concentrations indicated between brackets: Bafilomycin (200 nM), MG132 (10 μM), 
Lactacystin (10 μM) and Torin1 (250 nM). Control cells received equal volumes of the vector.  
 Cells were starved by replacing the culture medium with EBSS (Earle’s Balanced Salt Solution), 
a medium that lacks both serum and aminoacids.  
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3.5. Biochemical analysis 
3.5.1. Cell collection and lysis 
 Confluent monolayers were washed twice with PBS and mechanically detached from the culture 
well with pipette tips in the presence of SDS-lysis buffer (50 mM Tris HCl pH 6.8, 2% SDS) 
supplemented with protease inhibitors (Roche). Complete lysis was obtaining by boiling the samples at 
95°C for 2 minutes. DNA released by the lysis was fragmented by repeated passages through an insulin 
needle. 
 Protein concentration was assessed with BCA Protein assay kit (from Thermo Scientific or 
Euroclone). 
3.5.2. SDS-PAGE and Western Blot 
 Polypeptides were separated with the Tris-glycine system using a vertical electrophoretic device. 
Before loading, samples were heated to 60°C for 2 minutes after adding 1/3 of volume of Denaturation 
Buffer (DB) 4X (8% β mercaptoethanol, 34% glycerol, 0,04% bromophenol blue). 
 Following separation by SDS-PAGE, proteins were transferred onto 0,45 μ m nitrocellulose 
membrane (either from Biorad or Perkin Elmer). When lipidated proteins, like LC3, levels were assessed, 
a PVDF membrane (Biorad) was used. After checking the quality of the SDS-PAGE run and of the 
protein transfer by Ponceau S staining (Euroclone), membranes were incubated o/n in blocking buffer 
(Tris-buffered saline (TBS) with 0,1% Tween and 5% dried skim milk) under agitation at 4°C. Blots were 
then returned to RT, and probed with primary antibodies diluted in the same solution. After 3 washes with 
blocking buffer, blots where incubated with secondary antibodies. Unbound antibodies were finally 
removed by washing the blots three times with TBS + 0,3% Tween, then three times with TBS + 0,1% 
Tween and finally with TBS alone. Peroxidase-conjugated secondary antibodies were revealed by 
chemioluminescence using the ECL system (Perkin Elmer). The films were digitized, and band intensities 
were determined with ImageJ software (National Institutes of Health) after calibration with the optical 
density calibration step table (Stouffer Graphics Arts).  Alternatively, Infrared dye-conjugated secondary 
antibodies were used. In this case, blots were scanned with the Odyssey CLx Infrared Imaging System 
(LI-COR Biosciences), and band intensities were determined with Image Studio software (LI-COR 
Biosciences). 
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3.5.3. P56S-VAPB expression analysis 
 To analyze the degradation of mutant VAPB, we took advantage of the Tet-Off system. Tet-Off 
clones were first allowed to express and accumulate the mutant protein for 5–6 days in the absence of 
Dox; then, to stop synthesis of the transgene, the antibiotic was reintroduced into the medium, and the 
levels of P56S-VAPB were subsequently analyzed during a chase period (Papiani et al., 2012).  
 Briefly, four days after removal of Dox, equal amounts of cells were seeded onto 35 mm Petri 
dishes containing a coverslip, and incubation in the absence of Dox was continued for another two days. 
At this time, the coverslips were fixed and stained with DAPI; nuclei from random fields were counted to 
assess that each dish contained an equal number of cells. Degradation of VAPB was followed after 
readdition of Dox to the medium and cells were collected after treatment with the indicated drugs and at 
the time intervals indicated in the figures. The collected cells were lysed with SDS-lysis buffer (see “Cell 
collection and lysis”) and all samples were brought to the same volume. Equal aliquots were then 
analyzed by SDS-PAGE-Immunoblotting. The levels of VAPB were normalized for minor variations in 
the number of plated cells using DAPI staining. 
 
3.6. Microscopy 
3.6.1. Equipment 
 Confocal images were acquired either with the Zeiss LSM 510 Meta confocal system or with the 
Perkin Elmer Ultraview spinning disk acquisition system (Yokogawa CSUX1-A3).  
The Zeiss system was equipped with a 405/488/543/ 633 dichroic (Carl Zeiss, Oberkochen, 
Germany) and with 10xPlanNeofluar, 20xECPlanNeofluar, 40xPlanNeofluar or 63xPlanApo lens. Alexa 
Fluor 488, GFP and Bodipy were acquired using the 488 line of the Argon/2 laser, and a 505–550 band 
pass emission filter. For Alexa Fluor 568, DyLight 549 and Rhodamine, the 544 line of the He/Ne laser 
was used in combination with a 560–615 band pass emission filter. For DyLight 633, the 633 line of the 
He/Ne laser was used in combination with a 650 long pass emission filter. DAPI was imaged using the 
405 diode laser and a 420–480 band pass emission filter. Low magnification DIC images were acquired 
with 20x objective and Nomarsky disk. 
 The Perkin Elmer spinning disk system was attached to a Zeiss Axiovert 200M microscope, and 
used to acquire Cholera toxin and Lamp1 staining. The system was equipped with a 405/488/561/640 
dichroic and a 63x objective PlanApo objective was used.  
 Wide-field images were acquired with an Axioplan (Carl Zeiss, Oberkochen, Germany), or a 
Nikon E600 microscope, both equipped with an AxioCam HRm digital camera (Zeiss).   
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3.6.2. Sample preparation, image acquisition and image analysis 
 All the image analyses described in the following sections were performed with ImageJ software. 
(i). Standard immunofluorescence 
 HeLa cells were plated on untreated coverslips, while in the case of NSC34 cells, coverslips were 
pre-coated with Matrigel (BD Biosciences). After washing with PBS, cells were fixed with 4% 
Paraformaldehyde (PFA) containing 4% sucrose for 20 minutes at 37°C. PFA was removed by rinsing 
four times with PBS. After two washes with HS-PBS (see below), cells were incubated for 20 minutes 
with blocking buffer with Triton to block non-specific binding sites and permeabilize membranes. Next, 
they were incubated with primary antibodies diluted in blocking buffer for 1h 30’, washed four times with 
HS-PBS and incubated with secondary antibody diluted in the same buffer for 1h. Cells were washed four 
times with HS-PBS, three with PBS and once with water and finally mounted with Mowiol (Sigma). 
DAPI was diluted in the last PBS wash to counterstain nuclei.  
Buffer compositions were as follows: 
2x Blocking buffer NaCl 0.9 M, Na+ Phosphate Buffer pH 7.4 40 
mM, Goat serum 33%, (+ Triton X100 0.6% 
when used for the permeabilization step) 
HS-PBS NaCl 500 mM, Na+Phosphate Buffer pH 7,4 
20 mM 
PFA 
 
PFA 4%, Sucrose 4%, Na+ Phosphate Buffer 
pH 7.4 120 mM 
 
(ii). PI4P Immunofluorescence 
 To stain PI4P, we followed the protocol described by (Hammond et al., 2009). In this paper, the 
authors show that to prevent the extraction of lipids (like PI4P) from the Golgi compartment, cells need to 
be fixed with 2% PFA, permeabilized with Digitonin and all steps performed at RT. 
Briefly, cells were fixed for 15 minutes at RT with 2% PFA, obtained by directly adding an equal 
volume of PFA 4% to the medium in the culture well. After rinsing four times with PBS+50 mM NH4Cl, 
cells were permeabilized with 20 μM digitonin diluted in Buffer A (20 mM Pipes pH 6,8, 137 mM NaCl, 
2,7 mM KCl) for 5 minutes. The permeabilizing agent was removed by three rinses with buffer A, 
followed by 45 minutes incubation with blocking buffer (buffer A supplemented with 50 mM NH4Cl and 
5% goat serum). Next, cells were incubated with PI4P and Giantin primary antibodies (diluted in buffer A 
+ 5% goat serum) for 1h 30 min, rinsed three times with buffer A and incubated with secondary 
antibodies for 1h. After three washes with buffer A, cells were post-fixed for 5 minutes with 2% PFA 
diluted in PBS, rinsed four times with PBS+NH4Cl (DAPI was added to the last wash), once with water 
and finally mounted. 
 To quantify the amount of PI4P in the Golgi region, 1.6 μm thick (0.4 μm interval) z-stacks 
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(approximately 30 cells for each sample) were acquired centered around the plane with maximum Giantin 
staining (x–y sections). For each section, a ROI corresponding to Giantin staining was outlined; the 
integrated PI4P fluorescence intensity of this region was determined, and summed over the entire stack. 
To avoid artifacts due to differing efficacy of digitonin permeabilization of different cells, this value was 
normalized to that of the Giantin staining summed over the entire stack.   
Images were acquired with identical parameters, taking care to remain below saturation in the 
PI4P and Giantin channels. 
(iii).  Ganglioside GM1 fluorescence staining  
 To stain the ganglioside GM1, we used fluorescent (488 conjugated) cholera toxin (Invitrogen) 
(Eidels et al., 1983). The staining procedure was the same as described in the standard 
immunofluorescence section, with the exception that PBS was used for all washes and instead of using 
the indicated blocking buffer, blocking and antibody incubations were performed with PBS supplemented 
with 0.5% BSA, 0.05% saponin, 50 mM NH4Cl. Note that also in this case a mild detergent at low 
concentration was used, in order to avoid extraction of the ganglioside. 
(iv).  Mask analysis of LAMP1 positive GM1 vesicles 
 To assess the percentage of GM1 vesicles positive also for LAMP1 staining, fixed cells were 
subjected to double staining with fluorescent cholera toxin and anti-LAMP1 antibody as described in the 
previous paragraph. To perform quantification, Z-stacks (approximately 30 cells for each condition) 
comprising the total height of the cells were acquired (X–Y sections at 0.4 μm intervals) to measure 
Cholera and anti-LAMP1 fluorescence. A single confocal plane, corresponding to the medial cellular 
plane, was used for quantification for each cell using ImageJ software. Briefly, a threshold was fixed to 
convert cholera toxin and LAMP1 staining into binary masks. Small and big elements were excluded 
from the analysis by creating a second mask that took into account only particles with dimensions 
between 20-200 pixels. Elements remaining in this secondary mask were automatically counted. Lastly, 
the “AND function” was applied to secondary masks of cholera toxin and LAMP1 to visualize those 
elements positive for both stainings that were automatically counted. This number was divided to that of 
total Cholera toxin positive elements to obtain the percentage of GM1 vesicles positive also for LAMP1 
staining. 
(v). VSVG transport assay 
 Hela cells induced or not induced to express P56S-VAPB were transfected with ts045VSVG-
EGFP. This is a temperature-sensitive mutant of VSVG that at 39°C is misfolded and ER retained, while 
at the permissive temperature of 32°C is correctly folded and can travel trough the secretory pathway 
(Bergmann, 1989). Immediately after transfection, cells were held at 39.3°C. After 24 h, they were 
brought to 32°C in the presence of CHX and incubated for the times indicated in the figures. 
3. Materials and Methods 	  
	  	   	   	   37	  
 To evaluate the amount of VSVG in the Golgi area at each time point, coverslips were fixed and 
processed for immunofluorescence with anti-Giantin and anti-myc (to visualize myc-P56S-VAPB) 
antibodies. 1.2 μm thick z-stacks (approximately 20 cells for each condition and time point) were 
acquired centered on the plane with maximum Giantin staining (x–y sections). For each section, a ROI 
corresponding to Giantin staining was outlined; the integrated EGFP fluorescence intensity 
(corresponding to VSVG staining) of this region was determined, and summed over the entire stack. This 
value was normalized to that of the entire cell, determined in each section in ROIs drawn around the 
periphery of the cell. 
 For determination of surface VSVG, cells were placed on ice, medium was replaced with pre-
chilled PBS++ (PBS supplemented with 0,5 mM CaCl2 and 1 mM MgCl2), and the samples were then 
transferred to the cold room. After two washes, cells were blocked with 0.1% BSA in the same buffer, 
and then incubated with anti-VSVG primary antibody diluted in blocking buffer for 1 h. Cells were 
washed 3 times, fixed with chilled PFA first at 4° for 10 min, then at RT for an additional 10 min. After 
blocking with 17% goat serum, the non-permeabilized cells were exposed to secondary anti-mouse 
antibody for 50 min at room temperature. After 5 washes, the cells were fixed again for 5 min with PFA, 
permeabilized with Triton-X100 and processed for immunofluorescence with polyclonal anti-VAPB and 
secondary anti-rabbit antibodies as described in the standard immunofluorescence section. To perform 
quantification, Z-stacks (15–30 cells for each condition and time point) comprising the total height of the 
cells were acquired (X–Y sections at 0.5 μm intervals) to measure EGFP and anti-VSVG fluorescence. 
 For both the Golgi and the surface quantification of VSVG, images were acquired with identical 
parameters, taking care to remain below saturation in the EGFP and anti-VSVG channels. 
(vi). Ceramide transport assay 
 Ceramide transport was assessed by incubating cells with Bodipy-FL-Ceramide (Thermo Fisher) 
(Toth et al., 2006). Unless otherwise stated, all steps were performed on ice with chilled buffers.  
 To remove serum, cells were washed twice with FBS-free medium. Next, they were incubated 
with 0.5 μM Bodipy-FL-Ceramide diluted in the same buffer for 20 minutes. The excess of Bodipy-FL-
Ceramide was removed by 3 washes with FBS-free medium. The sample corresponding to time zero (T0) 
was immediately fixed for 5 minutes with PFA + Glutaraldheyde (GA) containing DAPI, washed twice 
with PBS+ 50 mM NH4Cl and mounted. Warm complete medium was added to the other samples and 
cells were placed at 37°C for the indicated time points. At the end of the incubation, the cells were fixed 
and mounted as indicated for T0. Images were acquired immediately after mounting.  
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Media and fixatives were as follows: 
FBS-free medium DMEM supplemented with P/S, L-
glutamine, 20 mM Hepes-Na pH 7.3, 
Complete medium DMEM supplemented with P/S, L-
glutamine, 20 mM Hepes-Na pH 7.3, 10% 
FBS 
PFA + GA PFA 4%, glutaraldehyde 0.05%, 0.2 M 
Hepes-Na pH 7.3 
 
3.7 Statistical analysis 
 The statistical analysis performed in each experiment is indicated in the figure legends along with 
p values. In general, either unpaired two-tailed Student’s t-test (Excel) or two-way ANOVA followed by 
Bonferroni’s post test (GraphPad Prism) were used.  
 
3.8 Antibodies 
 
 The primary and secondary antibodies used in this study are described in the following two 
tables. 
3.8.1 Primary antibodies 
 
Antigen Species Origin Working Dilution Application 
Actin Mouse Sigma  1:1000 WB 
ChAT Goat Millipore   1:500 WB 
GAP43 Mouse Sigma 1:2000  WB 
GAPDH Rabbit Santa Cruz   1:4000 WB 
GFP  Rabbit MBL 1:500  WB 
Giantin Rabbit 
Gift from Dr. Dr. M. Renz 
(Institute of Immunology and 
Molecular 
Genetics, Karlsruhe)  
1:800  IF 
Giantin Rabbit Synaptic Systems 1:500  IF 
GM130 Rabbit Gift from Dr. A. De Matteis (TIGEM, Naples)  1:2000 IF 
HA (71550) Rabbit Invitrogen 1:1000/ 1:400  WB/IF 
HA (SC805) Rabbit Santa Cruz 1:200  WB/IF 
Lamp (ab24170) Rabbit  Abcam 1:1000  IF 
LC3 (L8918) Rabbit Sigma  1:750 WB 
Myc (9E10) Mouse Santa Cruz 1:500  WB 
Myc (9E10) Mouse Sigma  1:1000 IF 
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Antigen Species Origin Working Dilution Application 
NF200 (N52) Mouse   Sigma 1:2000 WB 
NF68 Rabbit Chemicon   1:300 WB 
nKHC Rabbit Gift from Dr. R.D. Vale (UCSF, San Francisco, CA, USA)  1:800  WB 
p62 (ab91526) Rabbit Abcam 1:5000  WB 
PI4P Mouse IgM Echelon  1:300  IF 
Synaptobrevin Mouse  Synaptic Systems 1:1000 IF 
Tubulin (B-5-1-2) Mouse Sigma 1:80000/ 1:1400  WB/IF 
VAPA Rabbit 
Gift from Dr. C.C. Hoogenraad 
(Utrecht University)(Teuling et al., 
2007) 
1:2500  WB 
VAPB Rabbit Produced in this study (Genevini et al., 2014) 
 1:1000/ 
1:200 WB/IF 
VSVG (IE9F9) Mouse Kerafast  1:500 IF 
3.8.2 Secondary antibodies 
 
Species reactivity Conjugation Dilution Origin Application 
Rabbit Peroxidase 1:150 000 Sigma WB 
Rabbit IRDye 800CW 1:15 000 Licor WB 
Mouse Peroxidase 1:150 000 Sigma WB 
Mouse IRDye 680RD 1:15 000 Licor WB 
Goat Biotin 1: 2 000 Sigma WB 
Streptavidin Peroxidase 1: 1 000 Jackson WB 
Rabbit Alexa Fluor 488 1: 300 Life Technologies IF 
Rabbit Dylight 549 1: 400 Jackson IF 
Rabbit Alexa Fluor 633 1: 400 Life Technologies IF 
Mouse Alexa Fluor 568 1: 300 Life Technologies IF 
Mouse (IgM) Rhodamine 1: 300 Santa Cruz IF 
Mouse Dylight 549 1: 400 Jackson IF 
Mouse Alexa Fluor 633 1: 400 Life Technologies IF 
 
 
 
 
 
 
 
4. Results 	  
	  	   	   	   40	  
4. Results 
 
The aim of my thesis is to dissect the contribution of mutant VAPB gain and loss of function in 
the development of ALS. To investigate a possible gain of toxic function, I used cellular models 
expressing moderate levels of P56S-VAPB. To investigate the consequences of loss of VAPB function, I 
generated NSC34 clones silenced for VAPB expression, and analyzed their capacity to differentiate as 
well as possible alterations in lipid metabolism. The results of these two lines of research are presented in 
sections 4.1 and 4.2 of this chapter.  
4.1. Effect of P56S-VAPB on proteostasis and intracellular transport 
 In this section, I will describe the results obtained with cells expressing moderate levels of mutant 
VAPB. First, I will analyze the degradation and stability of the mutant protein; second, I will show 
experiments aimed at unrevealing toxic effects of P56S-VAPB on general proteostasis and vesicular 
transport. All the results presented in this section  have been recently published (Genevini et al., 2014). 
4.1.1. P56S-VAPB is cleared exclusively by the proteasome under basal conditions, but can 
be degraded by stimulated autophagy. 
 To investigate the mechanism of P56S-VAPB degradation, we used the HeLa Tet-Off cell line 
that was already available and characterized in our laboratory (Fasana et al., 2010) (Papiani et al., 2012). 
In this cell line, expression of mutant, myc-tagged, VAPB is repressed by the presence of Dox, and 
induced by removal of the antibiotic from the medium. As already shown in my laboratory, mutant 
VAPB in these cells is expressed at levels close to those of the endogenous protein (Fasana et al., 2010) 
(Papiani et al., 2012).  
 To analyze P56S-VAPB clearance, cells were grown in induction medium for 6 days to allow the 
production and accumulation of the mutant protein and were shifted to Dox-containing medium on the 
day of the experiment to block the expression of the transgene. Within nine-ten hours, approximately 2/3 
of P56S-VAPB was degraded (Fig. 4.1A,B). To assess whether the degradation was mediated by 
autophagy or the proteasome, we treated cells with drugs that selectively inhibit each of these pathways. 
Autophagy was blocked by treatment with either 3-MA or the proton pump blocker Bafilomycin, while 
the proteasome either by MG132, used in our previous study (Papiani et al., 2012), or lactacystin. As 
shown in Fig. 4.1A and B, P56S-VAPB degradation was prevented by both proteasomal inhibitors, while 
the autophagy blockers were without effect.  
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Figure 4.1: P56S-VAPB is degraded by the proteasome and by activated, but not basal, autophagy.  
A: Immunoblotting analysis of degradation of P56S-VAPB in the presence or absence of proteasome or autophagy 
inhibitors. 3 h after the inhibition of transcription of the P56SVAPB transgene by addition of Dox to the media 
(lanes 2 and 7), cells were either left untreated (lanes 3 and 8), treated with the autophagy inhibitor Bafilomycin 
(Baf) or with the proteasome inhibitors MG132 (MG) or Lactacystin (Lact) for 6–7 h, as indicated. Control (Ctl) 
cells were grown in the presence of Dox. Equal aliquots of each sample were loaded (see Methods). The lower panel 
shows Ponceau staining of the blotted gel region, as loading control. The vertical white line (here and in panel D) 
juxtaposes lanes deriving from the same blot exposure. The position of the 25 kDa size marker is indicated. B: 
Quantification (means from 2–5 experiments +SEM) of P56S-VAPB remaining at 10 h after Dox addition in the 
presence or absence of drugs, as indicated, compared to levels measured at 3 h *: p = 0.013 and 0.025 for MG132 
and lactacystin treated samples vs untreated by Student’s t test. respectively. The difference between 3-MA or 
bafilomycin-treated samples and untreated was non-significant (ns). C: Equal amounts of protein of the samples of 
lanes 3 and 4 of panel A were analyzed for p62 by immunoblotting, to control for inhibition of autophagy by 
bafilomycin. Actin was probed as loading control. D: Effect of starvation on clearance of P56S-VAPB. 3 h after 
addition of Dox to the media (lane 2), cells were either left untreated (lane 3), or treated with bafilomycin (Baf) or 
MG132 (MG), as indicated, for 6 h; the samples of lanes 6–8 were also starved during the incubation with or 
without the drugs. Control (Ctl) cells were cultured in presence of Dox. Ponceau staining of the blotted region is 
shown in the lower panel. E: Quantification of three experiments (means +S.E.M.) of P56S-VAPB remaining 9 h 
after Dox addition under the indicated conditions compared to levels measured before drug treatment and/or 
starvation at 3 h after Dox addition. *: p = 0.036 by Student’s t test; ns, non significant (Genevini et al., 2014). 
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Failure of autophagy blocking drugs to inhibit P56S degradation could be due to inactivity of 
these compounds. To evaluate the activity of Bafilomycin, we assessed levels of the autophagy receptor 
p62/SQSTM1 (to which we refer here as p62). p62 is degraded in autolysosomes and its levels increase 
under conditions of autophagy inhibition (Klionsky et al., 2012). As shown in Fig. 4.1C, p62 levels were 
higher in Bafilomycin-treated cells compared to controls, confirming that this drug is effective. The 
results illustrated in Fig. 4.1A–C confirm and extend our previous results that indicated that under basal 
conditions P56S-VAPB is degraded exclusively by the proteasomal pathway, and that autophagy is not 
involved (Papiani et al., 2012).  
 We then asked whether the inclusions could become substrate for induced autophagy. To this end, 
we compared the rate of degradation of P56S-VAPB under normal or starvation conditions, a treatment 
that enhance autophaghy (Fig. 4.1D,E). Starvation was performed by replacing the normal culture 
medium with the serum and aminoacid-free medium EBSS. This stimulates cells to activate autophagy to 
degrade proteins in order to obtain new aminoacids. As described previously, we let cells accumulate the 
mutant protein for six days before adding Dox and analyzing P56S-VAPB levels. Nine hours after Dox 
addition, the amount of the mutant protein in starved cells were reduced to less than one half those of 
non-starved cells (Fig. 4.1D and E). Under starvation conditions, the inhibition of P56S-VAPB 
degradation by MG132 was less effective than under basal conditions, suggesting that the enhanced 
degradation was due to autophagy. This was confirmed by the observation that Bafilomycin rescued the 
excess degradation observed in starved cells, so that Bafilomycin-treated starved cells had P56S-VAPB 
levels similar to non-starved cells.  
 Thus, whereas degradation of the P56S-VAPB is exclusively by the proteasomal pathway under 
basal conditions, the mutant protein may become an autophagosomal substrate under conditions that 
activate autophagy.  
4.1.2. Neither proteasome-mediated degradation nor autophagic flux are altered by P56S-
VAPB inclusions. 
 Alterations in proteostasis represent an important mechanism of proteotoxicity of pathogenic 
aggregates in ALS (Powers et al., 2009). Furthermore, interference with both these mechanisms by P56S-
VAPB overexpressing cells has been reported both in in vitro and in vivo models (Moumen et al., 2011) 
(Aliaga et al., 2013). We therefore investigated whether induction of the expression of P56S-VAPB 
inclusions in the HeLa Tet-Off cell line interferes with one or both of these pathways.  
To investigate a possible interference with the proteasome, we analyzed the clearance of a 
substrate of ER associated degradation (ERAD), a pathway involved in the extraction of substrates from 
the ER, followed by their ubiquitination and delivery to the proteasome (Bernasconi and Molinari, 2011). 
The substrate we chose to analyze is the CD3 complex δ chain (CD3δ), a subunit of the T-cell receptor. 
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This protein, when expressed in the absence of the other members of the complex, is recognized by the 
quality control system of the ER and degraded by ERAD (Yang et al., 1998). HA-tagged CD3δ was co-
transfected for 24 hours with soluble EGFP in cells expressing or not P56S-VAPB. Since not all induced 
cells have detectable P56S-VAPB inclusions, soluble EGFP was used to check by immunofluorescence 
that inclusion-positive and negative cells were comparably transfected. We quantified the distribution of 
P56S-VAPB inclusions in transfected and non-transfected cells (Fig. 4.2 C). In two separate experiments, 
inclusions were detected in 52 and 44% of total cells and in 64 and 47% of EGFP-positive cells 
(approximately 300 cells from random fields analyzed in each experiment), suggesting that inclusion 
positive and negative cells are equally transfected. To analyze CD3δ degradation, cells were treated with 
cycloheximide (CHX) for three hours to block translation and selectively look at the degradation of the 
target substrate. This treatment did not affect levels of EGFP nor tubulin (Fig. 4.2A), but strongly reduced 
CD3δ levels (Fig. 4.2A,B). Importantly, after CHX treatment, CD3δ levels were comparable in cells 
induced or not induced to express P56S-VAPB, suggesting that the mutant protein does not interfere with 
ERAD. 
 To investigate autophagosomal flux, we analyzed the behavior of two autophagosome markers 
(p62 and LC3) after induction of autophagy either by starvation with EBSS (described in the previous 
section) of by pharmacologically inhibiting mTOR (mammalian Target Of Rapamycin) with Torin1 
(Thoreen et al., 2009). mTOR is a kinase involved in cellular metabolism, growth, proliferation and most 
importantly is a major negative regulator of autophagy, so its inhibition results in a strong activation of 
this degradative pathway. As mentioned before, endogenous p62 decrease following autophagy 
stimulation. We measured its levels in cells grown in the absence or presence of Dox and treated with 
EBSS or Torin1. Levels of remaining p62 are comparable between cells induced or not to express P56S-
VAPB with both autophagy-stimulating treatments (Fig. 4.2 D, top). Therefore, induction of P56S-VAPB 
expression did not interfere with p62 degradation. In similarly treated cells, we examined the generation 
of the lipidated form of LC3 (LC3-II), a reaction that occurs when LC3 is recruited to nascent 
autophagosomes (Kabeya et al., 2000). In our HeLa Tet-Off cell line, the lipidated (LC3-II) form 
predominated already under basal conditions (Fig. 4.2D, lanes 1 and 4); the non-lipidated form (LC3-I) 
decreased after both Torin 1 treatment and starvation and differences between the ratio of the two forms 
were not detected between cells grown in the presence or absence of Dox (Fig. 4.2E).  
 From these experiments we can conclude that presence of moderate levels of P56S-VAPB does 
not interfere with general proteostasis. 
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Figure 4.2: Lack of interference of P56S-VAPB inclusions with general proteostasis.  
A: Immunoblotting analysis of the degradation of the ERAD substrate CD3δ. Induced or not induced cells, co-
transfected with plasmids specifying HA-CD3δ and EGFP, were treated with CHX for 3 h as indicated. Equal 
amounts of protein (30 mg) were loaded. B: Quantification of three experiments (means+SEM) of  CD3d remaining 
3 h after CHX addition compared to untreated samples. Values were normalized to EGFP. By two-way Anova, the 
presence of Dox had no significant effect on CD3δ, while the effect of CHX was very significant (p = 0.0014). C: 
Immunofluorescence analysis of induced P56S-VAPB-Tet-Off cells co-transfected with HACD3d and EGFP. The 
arrows in the merge panel indicate EGFP positive cells containing P56S-VAPB inclusions, revealed with anti-myc 
antibodies (left panel). Approximately equal proportions of cells with or without detectable inclusions were 
transfected (see text). The arrowhead indicates a nontransfected cell positive for P56S-VAPB. Asterisks indicate 
non-transfected cells negative also for VAPB. Nuclei were stained with DAPI (blue). Scale bar, 10 μm. D: 
Immunoblotting analysis of the effect of P56S-VAPB inclusions on autophagic flux. Cells expressing or not 
expressing P56S-VAPB where either left untreated or treated for 3 h with Torin1 or starvation medium (EBSS), as 
indicated. The levels of p62, as percentage of the values in untreated cells are indicated below the lanes. Values 
were normalized to actin content. E: Quantification of three experiments (means+SEM) of LC3II/ LC3I ratio of 
cells treated either with Torin 1 or with starvation medium, in comparison to untreated cells. Two-way Anova 
analysis reported that the source of variation between samples was due to autophagocytosis induction (non-treated 
vs Torin 1: p,0.01 and ,0.05 for non-induced and induced cells, respectively) and not to P56S-VAPB expression 
(Genevini et al., 2014). 
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4.1.3. In a model motoneuronal cell line, P56S-VAPB inclusions are degraded by the 
proteasome and not by basal autophagocytosis  
 The results regarding the degradation of P56S-VAPB were obtained in HeLa cells, but ALS is a 
pathology that primary affects MNs. Therefore, we wanted to check if MNs are able to degrade the 
mutant protein like epithelial cells. For this purpose, we created NSC34 cell lines stably expressing wild-
type or P56S-VAPB under the tetracycline-repressible promoter. As described in the Material and 
Methods chapter, these are the best available cell line to study motorneuronal diseases.  
As shown in Fig. 4.3A, wt myc-VAPB was distributed throughout the cytoplasm, in a dense 
reticular network, as expected for an ER protein, whereas the P56S mutant formed inclusions similar to 
those observed in HeLa cells and in transiently transfected NSC34 cells (Fasana et al., 2010) (Suzuki et 
al., 2009).  
 We then investigated the mechanism of degradation of mutant VAPB as done for the HeLa cell 
line. After inducing cells to express the mutant protein for four days in Dox-free medium, we additionally 
treated them for twelve hours with Na+Butyrate to enhance the expression of the transgene. Na+Butyrate 
is an inhibitor of histone deacetylases (HDAC) and general enhancer of gene expression (Kruh, 1982). To 
perform the experiment, medium was replaced with one containing Dox and, as indicated in Fig. 4.3B, 
drugs that inhibit either the proteasome (MG132) or autophagy (Bafilomycin). As shown in Fig. 4.3B, 
levels of P56S-VAPB decrease between three and ten hours after exposure to Dox, indicating that this 
cell line can effectively degrade P56S-VAPB. The degradation of the mutant protein was nearly 
completely reversed by MG132, while Bafilomycin was without effect. The efficacy of Bafilomycin 
treatment was confirmed by the increase of p62 content as previously performed for HeLa cells. 
  We also analyzed the degradation of the mutant protein by immunofluorescence. After Dox 
addition, we saw a decrease in VAPB-positive aggregates. The inclusions were stabilized by treatment 
with MG132, but not with Bafilomycin (Fig. 4.3C), in agreement with the results obtained by western 
blot.  
Thus, under basal conditions, P56S-VAPB inclusions in NSC34 cells are cleared by the same 
proteasome-mediated mechanism as observed in HeLa cells.  
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Figure	  4.3: P56S-VAPB inclusions in a model motoneuronal cell line are degraded by the proteasome.  
A: Immunofluorescence analysis of NSC34 Tet-Off cells induced to express myc-wt-VAPB (left) or myc-P56S-
VAPB (right). The upper panel shows anti-myc immunofluorescence, the lower one the superposition of myc 
staining with phase contrast. The inset of the upper left panel shows a 2 fold enlargement of the boxed area, and 
illustrates the web-like distribution of wt VAPB typical of an ER protein. Scale bar: 15 μm. B: Degradation of 
P56S-VAPB stably expressed in NSC34 cells. Induced cells were supplemented with Dox; 3 h thereafter the cells 
were either left untreated or treated with MG132 (MG) or Bafilomycin (Baf) for 7 h. Control (Ctl) cells were grown 
in the presence of Dox. Equal aliquots of each sample were loaded. The lower panel shows Ponceau staining of the 
blotted gel region; the positions of the 25 and 37 kDa size marker are indicated. The vertical white line indicates 
removal of irrelevant lanes form the image. The levels of P56S-VAPB, as percentage of values in untreated cells at 
3 h after Dox addition, are indicated below the lanes. p62 immunoblotting was performed to check the efficacy of 
bafilomycin to inhibit autophagy (upper). C: Confocal analysis (single sections are shown) of P56S-VAPB 
inclusions stained with anti-myc antibody (red) at 3 h after Dox addition (left) and 7 h later in the presence or 
absence of the indicated drugs. Nuclei were stained with DAPI. The number and size of the inclusions decreased in 
the absence of drugs or in the presence of Bafilomycin, but remained similar to the 3 h cells when MG132 was 
present. Scale bar, 10 μm (Genevini et al., 2014).    
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4.1.4. Close relationship between P56S-VAPB inclusions and the Golgi Complex  
 In most cases P56S-VAPB inclusions are localized close to the nucleus, in a position similar to 
that of the Golgi apparatus. Since disruption of the Golgi in neurons is a hallmark of many 
neurodegenerative diseases, including ALS (Gonatas et al., 2006) (van Dis et al., 2014), we wanted to 
investigate by immunofluorescence the relationship of the inclusions with the Golgi. 
  For this purpose, we compared the distribution of P56S-VAPB in our HeLa Tet-Off cells with 
that of two different Golgi markers: GM130 (Golgi Matrix protein of 130 KDa), which is preferentially 
localized to the cis face of the Golgi ribbon, and giantin, which is present on Golgi vesicles. With both 
stainings, the inclusions appeared to be embedded within the Golgi complex (Fig. 4.4), suggesting a 
possible interference of the aggregates with Golgi functions. 
 
 
 
	  
Figure 4.4. Close relationship between P56S-VAPB inclusions and the Golgi Complex.  
Induced HeLa Tet-Off cells were doubly immunostained with anti-myc antibodies, to reveal P56S-VAPB, and 
antibodies against the Golgi proteins GM130 or giantin, as indicated. Nuclei, stained with DAPI, are shown in the 
merge panel. Shown are maximum intensity projections of z-stacks. Scale bars: upper row, 10 μm; middle and lower 
row 5 μm (Genevini et al., 2014).  
4. Results 	  
	  	   	   	   48	  
4.1.5. P56S-VAPB inclusions do not interfere with the intracellular transport of Vesicular 
Stomatitis Virus Glycoprotein (VSVG)  
 The observation of the previous section suggested that the tight relationship between P56S-VAPB 
inclusions and the Golgi complex might underlie interference of the aggregates with transport through the 
secretory pathway, as reported in cells transiently transfected with mutant VAPB (Prosser et al., 2008).  
 To investigate the functionality of the secretory pathway in cells expressing moderate levels of 
P56S-VAPB, we allowed HeLa Tet-Off to accumulate the mutant protein (as described in the first 
section) and then transfected them with cDNA coding for the ts045 version of the secretory membrane 
protein VSVG coupled to GFP. This is a temperature sensitive transmembrane protein that at 39°C is 
misfolded and accumulates in the ER. By shifting the temperature to 32°C, VSVG is correctly folded and 
can travel through the secretory pathway until the plasma membrane. Because of these characteristics, 
ts045-VSVG-GFP has been widely used to study protein transport (Bergmann, 1989).  
 We first compared the time course of accumulation in the Golgi of transfected VSVG. After 
growth for five days in induction medium, cells were transfected placed at 39°C for 24 hours to allow 
expression and accumulation of VSVG-GFP. Next, they were treated with CHX and placed at 32°C for 
the time indicated in Fig. 4.5. After processing for immunofluorescence, random cells were imaged and 
Golgi localization of VSVG was evaluated by superposition on the giantin-positive area of the cells. In 
the case of the induced sample, we did not consider cells lacking visible inclusions. As shown in Fig. 4.5, 
VSVG accumulated rapidly in the Golgi, with maximum accumulation at 30 min after release of the 
temperature block, with similar time course in induced and non-induced cells. At later times, Golgi 
fluorescence decreased, with concomitant appearance of surface staining. The experiment of Fig. 4.5 
indicates that transport of VSVG from the ER to the Golgi is not impaired by the presence of mutant 
VAPB inclusions.  
 To quantify transport to the cell surface, I transfected and incubated cells in the same way as in 
the experiment of Fig. 4.5, but at the indicated time points (Fig. 4.6) the non-permeabilized cells were 
exposed to an antibody that recognizes the lumenal/extracellular domain of VSVG (see Materials and 
Methods). Cell surface fluorescence was determined at various times after release of the temperature 
block. As shown in Fig. 4.6, arrival of VSVG at the cell surface was not delayed in the induced, 
compared to the non-induced cells, indicating that the intracellular transport of this model glycoprotein is 
not affected by the presence of P56S-VAPB inclusions in tight association with the Golgi complex. 
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Figure 4.5. Transport of VSVG to the Golgi Complex occurs normally in cells expressing P56S-VAPB 
inclusions.  
A: HeLa-TetOff cells, induced (-Dox, right) or not induced (+Dox, left) to express myc-P56S-VAPB, were 
transfected with VSVG-GFP at 39.3°C. After 24 h, one coverslip of each sample was fixed (0 min), while the others 
were shifted to 32°C and fixed after incubation for the indicated times. Cells were stained with anti- Giantin (red) 
and anti-myc (blue) antibodies. Maximum intensity projections of z-stacks are shown. The cell boundaries at the 30 
min time point are indicated by the white line in the merge panel. Acquisition parameters were the same in all 
images. Scale bar, 10 μm. B: Time course (means ± SD) of VSVG transport through the Golgi. Significant 
differences between induced or non-induced samples were not detected by Student’s t-test (Genevini et al., 2014). 
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Figure 4.6. Transport of VSVG to the cell surface occurs normally in cells  expressing P56S-VAPB inclusions.  
A: HeLa-TetOff cells, induced (-Dox) or not induced (+Dox) to express myc-P56S-VAPB, were transfected with 
VSVG-GFP at 39.3°C. After 24 h, cells were shifted to 32°C. At the indicated times, the cells were chilled and 
incubated with anti-lumenal domain of VSVG under non- permeabilizing conditions (red). The cells were then 
permeabilized and stained with anti-VAPB antibodies (blue in merge panel - see Methods). Total VSVG 
(intracellular+surface) was revealed by GFP fluorescence (green). Maximum intensity projections of z-stacks are 
shown. The acquisition parameters were the same in all images. Scale bar, 10 μm. B: Time course (means ± SD) of 
VSVG surface labeling normalized to total GFP fluorescence. Significant differences between induced or non-
induced samples were not detected by Student’s t-test (Genevini et al., 2014). 
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4.1.6. Summary of the results obtained with cellular models expressing moderate levels of 
P56S-VAPB. 
 In this section I described the results obtained with P56S-VAPB expressing cell lines. I confirmed 
that under basal conditions mutant VAPB is quickly cleared from cells through the proteasome, without 
any apparent involvement of autophagy. This result was extended also to the motorneuronal cell line 
NSC34.  The situation is different after autophagy stimulation: in these conditions, P56S-VAPB becomes 
a substrate also for autophagic degradation. We next analyzed whether the presence of mutant P56S-
VAPB could interfere with protein degradation pathways, as this is has been suggested as a pathogenic 
mechanism of ALS. However, we didn’t detect any alterations nor in the proteasome nor in autophagy. 
We next assessed that inclusions are in close relationship with the Golgi apparatus, suggesting a possible 
negative effect on the secretory pathway. However, we saw no alterations in the transport of the model 
protein VSVG, suggesting that the presence of moderate levels of P56S-VAPB doesn’t alter protein 
transport. 
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4.2. Effect of VAPB silencing on the NSC34 motor neuronal cell line. 
  Most of the results of the previous section were obtained with Hela cells. However, ALS is a 
pathology that primarily affects motor neurons. Therefore, we decided to continue our work using 
exclusively NSC34 cells. As already described, NSC34 is a hybrid cell line produced by fusing 
motorneuronal-enriched spinal cord derived cells with neuroblastoma, thus obtaining an immortalized cell 
line with motorneuronal characteristics.  
 As the aim of this work is to dissect the different contribution of mutant VAPB gain and loss of 
function in the pathogenesis of ALS, we developed stable VAPB-silenced NSC34 cell lines to analyze the 
effects of VAPB downregulation in a motorneuronal background. First, I will describe our 
characterization of the differentiation process of NSC34 cells (section 4.2.1), then the generation and 
characterization of silenced NSC34 cell lines (section 4.2.2), and finally their use in experiments 
regarding lipid metabolism and neurite extension (section 4.2.3), as VAPB has a role in both these 
phenomena. 
4.2.1. Differentiation of wt NSC34 cells.  
  Different protocols have been described in literature to allow the differentiation of NSC34 cells 
into a more motorneuronal phenotype. The common strategy is to reduce serum content in the culture 
media. A new recent protocol improves this strategy by addition to the culture media of all-trans retinoic 
acid, a drug with known impact on morphology and biochemical differentiation of neuronal precursor 
cells (Maier et al., 2013). As the aim of this work is to study models of Amyotrophic Lateral Sclerosis, 
we applied the protocol described by Maier in order to be able work with more motorneuronal-like cells. 
In this section I will describe the characterization of differentiated NSC34 that we carried out. 
(i). Morphological analysis 	  
  To perform these experiments, cells were left in differentiating medium (see Materials and 
Methods) for six days. As can be appreciated by the phase contrast picture (Fig. 4.7A), following 
differentiation NSC34 extend long neurites, which can exceed 200 μm. By immunofluorescence staining, 
we observed a redistribution of the synaptic vesicle marker synaptobrevin (Fig. 4.7A and B): in non 
differentiated (ND) cells, it stains mostly the cell body, while after differentiation (Diff) it is concentrated 
in the neurite terminals. By higher magnification (4.7B), it could be appreciated that synaptobrevin is 
distributed throughout the whole cell body in ND, with some perinuclear regions more intensely stained. 
Instead, in differentiated cells the cell body appears dark and positive staining is observed only in neuritis 
and growth cones. This could reflect the fact that synaptobrevin is first inserted into the endoplasmic 
reticulum membrane and then transported through the Golgi apparatus to synaptic-like vesicles (Kutay et 
al., 1995).   
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  Sphingolipids are essential components of neuronal membranes. For this reason, we analyzed the 
localization of GM1 gangliosides. To assess their distribution, we labeled cells with fluorescent cholera 
toxin, a drug that specifically binds GM1 (Fig. 4.8). By fluorescence analysis, we observed a marked 
difference in the distribution of these lipids in non-differentiated and differentiated cells: in the first case, 
most of cholera toxin staining is found intracellularly in vesicular structures with only minimal staining 
on the cell surface. Following differentiation, clear staining of the plasma membrane is observed (Fig. 
4.8A).  
  To better characterize the GM1-positive vesicular compartment, we performed a double staining 
with cholera toxin and the late endosome-lysosome marker LAMP1 (Lysosome Associated Membrane 
Protein 1). LAMP1 shows a vesicular localization both in ND and differentiated cells. In some cases, 
LAMP1 surrounds GM1 vesicles in control cells (Fig. 4.8B). However, following differentiation, 
LAMP1-vesicles appear smaller and the staining less intense compared to basal conditions and do not 
follow GM1 redistribution to the plasma membrane. To assess whether GM1 and LAMP1 stain the same 
compartment in ND cells, we calculated the percentage of GM1 vesicles positive also for LAMP1 by 
mask analysis (see Material and Methods for details) (Fig. 4.8B and C). We found that approximately 
50% of GM1 vesicles are also stained by LAMP1. 
 
	  
Figure 4.7: Neurite extension and synaptobrevin redistribution following NSC34 differentiation for six days. 
Panel A shows synaptobrevin immunofluorescence superimposed on DAPI staining (blue) and on the DIC image. 
The image was acquired with the Zeiss Meta confocal setup. Panel B shows higher magnification wide-field 
immunofluorescence images, illustrating synaptobrevin redistribution after differentiation. ND: not differentiated; 
Diff: differentiated. White arrowheads in A and B show synaptobrevin accumulation at neurite terminals. In panel 
B, cell boundaries are outlined in white in differentiated cells. CB: Cell Body. Scale bars: 50  and 20 μm in A and B, 
respectively. 
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Figure 4.8: Ganglioside GM1 and LAMP1 localization in non-differentiated (ND) and six day differentiated 
(Diff) NSC34 cells. 
A: Representative images of ganglioside GM1 (revealed by fluorescent cholera toxin stainin - green) and LAMP1 
(red) in non-differentiated and differentiated cells. Maximun projections of z-stacks are shown. Images were 
acquired with identical parameters. Scale bar: 20 μm. The boxed area in the ND merge is represented in the enlarged 
image of panel B. B: single confocal plane (boxed region in panel A) of not differentiated cells stained for 
ganglioside GM1 (green) and LAMP1 (red). Scale bar: 5 μm. C: quantification with mask analysis of the percentage 
of GM1 vesicles positive also for LAMP1. Graph shows mean ± SD. 29 cells were analyzed. 
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(ii). Biochemical analysis 	  
 To assess differentiation by biochemistry, we analyzed several neuronal markers by western blot 
after six days of differentiation. We chose to analyze ChAT (Choline Achetil Transferase) because it is 
the key enzyme for the synthesis of acetylcholine, the neurotransmitter typical of lower motorneurons, 
and its increase is specific for motorneuronal differentiation; GAP43 (Growth Associated Protein 43) 
because it is expressed at high levels in neuronal growth cones during development and axonal 
regeneration and is therefore considered a general marker of neuronal differentiation; high and low 
molecular weight neurofilament subunits (NF200 and NF68) as they are intermediate cytoskeletal 
components typical of neuronal cells and finally the neuronal specific form of Kinesin Heavy Chain (n-
KHC).  
 We observed an increase in GAP43 and in ChAT (Fig. 4.9A and B), but, unexpectedly, we saw a 
reproducible ~ 50% decrease in NF200 and NF68 levels and in n-KHC (Fig. 4.9C and D).  
 As the focus of this work is to study VAPB in a motorneuronal disease, we next analyzed the 
expression of both VAP isoforms following differentiation (Fig. 4.10). Interestingly, both VAPA and 
VAPB are upregulated. The increase in VAPB levels is higher than that of VAPA: indeed, we observed a 
50% increase in VAPA (Fig. 4.10B) and a statistically significant (p= 0.014) doubling in VAPB levels 
(Fig. 4.10D).  
(iii). Summary of the results on NSC34 differentiation with retinoic acid 	  
  In this section I analyzed the differentiation of NSC34 cells with the method described by Maier. 
Probably the most striking feature of NSC34 differentiation is the extension of long neurites, but other 
changes occur as well. By immunofluorescence we showed the redistribution of synaptobrevin, 
gangliosides GM1 and LAMP1. Moreover, we saw a change in the levels of several neuronal markers, 
which do not always behave as expected: indeed, while GAP43 and ChAT increase as expected, NF200, 
NF68 and nKHC decrease. Interestingly, VAPA and B levels also increase following differentiation.  
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Figure 4.9: Immunoblotting analysis of the indicated neuronal markers in non-differentiated (ND) and six 
day differentiated (Diff) NSC34 cells. 
Except for ChAT, which was revealed by ECL, all blots were acquired with the LiCor Odessey apparatus. Equal 
amounts of protein (25 μg) were loaded in each lane. The levels of each marker after differentiation, as percentage 
of the values in non-differentiated cells, are indicated below the lanes. All values were normalized to tubulin or 
actin, used as loading controls. 
 
 
 
Figure 4.10: VAP protein levels increase following differentiation of NSC34 cells. 
Equal amounts of protein (25 μg) deriving from non-differentiated (ND) or six day-differentiated (Diff) cells were 
loaded in each lane, and analyzed for VAPA (panel A) or VAPB (panel C). The graphs in panels B and D shows 
means + SEM from two and four independent experiments for VAPA and B, respectively . * p = 0.014 
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4.2.2. Generation and characterization of VAPB silenced NSC34 clones  
(i). Establishment of VAPB-silenced clones 	  
 For the establishment of stable silenced VAPB cell lines we decided to use the pSUPER.neo.GFP 
plasmid, that enables the production of an shRNA which is processed into a mature and active siRNA. 
Downregulation efficiency and target specificity are essential characteristics of siRNAs to be considered 
when planning a silencing experiment. For this reason, before producing pSUPER.neo.GFP plasmids, we 
transiently silenced NSC34 with different siRNAs (Fig. 4.11). We used a mixture of 3 siRNAs (see 
Materials and Methods for sequences) from Invitrogen that together have a high silencing power. In 
parallel, we tested each siRNA by itself. All three siRNA were able to downregulate VAPB when 
compared to the sample treated with a scrambled oligonucleotide duplex. However, siRNA 2 had the 
poorest downregulating efficiency and was therefore excluded from the following steps. To check 
specificity of the siRNA, we assessed levels of VAPA, which were unaffected in all conditions.  
 We cloned siRNA 1 and siRNA 3 into pSUPER.neo.GFP vectors and stabily transfected them in 
NSC34. Unfortunately, no positive clones were obtained from pSUPER.neo.GFP(siRNA1) transfected 
cells (data not shown).  
 From pSUPER.neo.GFP(siRNA3) transfected cells we obtained two positive clones: #1 and #6 
(termed shRNA-VAPB clones). As control, we transfected cells with pSUPER.neo.GFP empty vector 
(termed vector-only clones) and obtained three clones: #11, #14 and #16 (Fig. 4.12). Clone #14 showed 
slow growth and was therefore excluded from further experiments.  
 Our two shRNA-VAPB clones showed different levels of downregulation: specifically, #1 and #6 
had VAPB levels reduced by ~90 and ~50% respectively. Thus, the #6 clone could be considered a model 
for haploinsufficiency, and we continued our experiments with both the lines.  
As observed in the experiments performed with siRNAs, VAPA levels were unaffected by VAPB 
silencing (Fig. 4.12A). pSUPER.neo.GFP plasmid codes also for a soluble GFP, whose expression was 
present in all stable clones as assessed both by biochemical and immunofluorescence analysis . However, 
GFP levels were not homogeneous when comparing different clones: #1 and #11 had higher GFP 
expression compared to #6 and #16. Of note, VAPB silencing and GFP expression seemed to correlate: 
#1 had strong VAPB downregulation and high GFP expression, while #6 mild VAPB downregulation and 
low GFP expression. This could indicate that in #1 more plasmid copies were stably inserted or that the 
insertion involved a more actively transcribed site in the chromatin. As indicated by immunofluorescence 
analysis, clones were homogeneous as more than 90% of the cells express GFP (Fig. 4.12B). 
 Downregulation of VAPB in clones #1 and #6 was stable over time: reduced levels of VAPB are 
observed after several weeks in culture (data not shown). 
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Figure 4.11: transient VAPB silencing in NSC34 cells. 
Immunoblotting analysis of NSC34 lysates following 48h transient siRNA silencing. Cells were treated with a mix 
of 3 VAPB-targeting siRNA, with each one individually or with a control duplex oligonucleotide (scramble), as 
indicated. VAPB and VAPA levels were assessed by immunoblotting. Tubulin was used as loading control. Equal 
amounts (25 μg) of proteins were loaded. 
 
   
	  
Figure 4.12: establishment of stable VAPB-downregulated NSC34 cell lines. 
A: immunoblotting analysis of lysates from positive NSC34-clones. shRNA-VAPB clones were obtained after 
stable transfection with pSUPER.neo.GFP encoding a VAPB targeting shRNA; vector-only clones were obtained 
after stable transfection with empty pSUPER.neo.GFP; untrasfected cells were included to show specificity of GFP 
staining. Equal amounts (25 μg) of proteins were loaded in each lane. B: immunofluorescence staining of soluble 
GFP expressed by stable clones transfected with pSUPER.neo.GFP vectors. Untransfected cells were included to 
show specificity of the staining. Nuclei were counterstained with DAPI. Images were acquired with identical 
parameters. Scale bar: 20 μm. 
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(ii). Differentiation of VAPB-silenced NSC34 	  
 Since we observed an increase in VAPB expression following differentiation with retinoic acid 
(Section 4.2.1, Fig. 3.10), we sought to understand whether the downregulation of VAPB could alter 
NSC34 differentiation. To perform this experiment, all stable clones were treated with differentiating 
medium for six days and next subjected to immunofluorescence or western blot analysis.  
 From phase contrast images we saw that both VAPB-silenced and control clones extended long 
neurites (Fig. 4.13), suggesting that no major defects in NSC34 differentiation were present following 
VAPB downregulation (however, see the section on neurite extension below). 
 We next analyzed different neuronal markers by western blot. As observed in the previous 
section, some neuronal markers increase following differentiation, while others unexpectedly decrease. 
ChAT levels increased in all clones with the exception of the control #16 (Fig. 4.14B). Levels of GAP43 
were also higher, even thought basal (non differentiated) expression vary among different clones (Fig. 
4.14C). In line with our previous observations, all clones showed a decrease in neurofilaments NF200 and 
NF68 (Fig. 4.14B and C). Finally we analyzed VAPB levels (Fig. 4.14A). As expected, in both 
downregulated clones VAPB expression didn’t increase. The control clone #16 showed an increase in 
VAPB expression as previously observed in non transfected cells. Strangely, VAPB levels in clone #11 
were stable.  
 Taken together, these results indicate that VAPB downregulation has no appreciable effect on the 
alterations of the levels of the analyzed neuronal markers occurring during differentiation. 
4.2.3. Effect of VAPB silencing on PI4P, on ceramide transport and on neurite extension of 
NSC34 cells 
(i) Analysis of PI4P levels in Golgi 	  
 As summarized in the Introduction, an important function of VAPB is its involvement in lipid 
transport at membrane contact sites between the ER and the Golgi. VAPs are responsible for the ER-
docking of lipid transfer proteins (LTP), which can also associate with the Golgi by binding the 
phosphoinositide PI4P. Therefore, PI4P and the VAPs work in concert to ensure correct localization of 
different LTPs. PI4P levels on the Golgi are precisely regulated by the LTP themselves: OSBP, a VAP-
binding protein, back-transfers PI4P to the ER where is quickly converted to PI by the phosphatase Sac1, 
whose function is stimulated by VAP. Alterations in LTP localization and Sac1 activity following VAP 
depletion might thus cause altered levels of PI4P. 
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Figure 4.13: shRNA-VAPB clones extend neurites following differentiation. 
Cells were differentiated for 6 days (Diff) or maintained in normal growth medium (ND) before fixing and staining.  
The phase contrast image shows whole cell morphology while DAPI counterstains nuclei. Scale bar: 50 μm.  
 
 
	  
 
Figure 4.14: Immunoblotting analysis of shRNA-VAPB clone differentiation. 
Cells were differentiated for 6 days (Diff) or maintained in normal growth medium (ND) before collection and lysis. 
Equal amounts (25 μg) of proteins were loaded for analysis of VAPB (A), ChAT and NF200 (B), NF68 and GAP43 
(C). GAPDH or tubulin were used as loading controls. 
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To assess this possibility, we analyzed PI4P content in the Golgi apparatus by 
immunofluorescence using a protocol that specifically maintains Golgi lipid composition (see Materials 
and Methods). As can be observed in Fig 4.16, we saw an increase in PI4P in the shRNA-clone #1, which 
has a strong VAPB downregulation. Instead, shRNA-clone #6, where VAPB is only mildly 
downregulated, behaved similarly to the control clones. The increase in PI4P content was already present 
in not differentiated cells and was maintained after differentiation (Fig. 4.15A).  
 We can conclude that strong, but not mild, VAPB downregulation can affect PI4P levels in the 
Golgi apparatus. 
(ii). Analysis of ceramide transport 	  
 Ceramide is synthetized in the ER but needs to be transported to the Golgi to be metabolized into 
complex sphingolipids. Two pathways exist for ceramide transport: a vesicular, CERT-independent and a 
CERT-dependent pathway. CERT is a LTP that needs binding to VAPs and PI4P to correctly localize at 
ER-Golgi membrane contact sites to perform its task.  
 To understand whether VAPB downregulation might alter ceramide flux to the Golgi, we 
performed analysis of ceramide transport by looking at localization of the fluorescent ceramide analogue 
Bodipy-FL-Ceramide (Toth et al., 2006). This molecule exhibits fluorescence in the 488 channel, so we 
first checked if this signal was covered by the soluble GFP expressed by stable clones. Fortunately, we 
found that the GFP signal is extremely weak compared to that of Bodipy-FL-Ceramide (Fig. 4.16C): in 
samples that did not received ceramide, the GFP fluorescence could not be appreciated when images were 
acquired with the same parameters used for ceramide-treated cells. The weak GFP signal could be seen 
only after digital enhancement of the 488 channel.  
Uptake of Bodipy-FL-Ceramide was performed on ice, in order to allow its accumulation in the 
ER and prevent its transport. Indeed, at the end of the incubation on ice the fluorescence signal was 
discernable on the ER and on the plasma membrane, the latter presumably due to Bodipy-FL-Ceramide 
bound to the cell surface before penetration into the cytosol. After a short ten min incubation at 37°C, 
Bodipy-FL-Ceramide accumulated in the Golgi (Fig. 4.16A).  
 To perform the experiment, we first differentiated cells for six days and then compared one 
shRNA-VAPB with one control clone. We chose to analyze clone #1 as it has a strong VAPB 
downregulation and was therefore more likely to reveal a defect. As readout, we assessed the percentage 
of cells with visible ceramide accumulation in the Golgi region.  VAPB-downregulated and control cells 
showed the same percentage of ceramide accumulation in the Golgi (Fig 4.16B).  
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Figure 4.15: PI4P accumulates in the Golgi apparatus of VAPB- silenced cells. 
A: quantification of PI4P staining normalized to giantin in Golgi apparatus in shRNA-VAPB and vector-only 
clones. ND: not differentiated; Diff: differentiated. Cells were differentiated for 6 days before fixing and staining. 
Non-differentiated cells were maintained in normal growth media. For each sample, 35-50 cells were analyzed. 
Graph shows mean ± SEM. * p<0,05; ** p<0,01; *** p<0,001 by two way ANOVA (Graphpad Prism) B: 
representative images of clone #1 and #16 stained with PI4P (red) and giantin (green). Maximum intensity 
projections of z-stacks are shown. Cell boundaries are outlined in white in the merge image. Scale bar: 20 μm. 
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We can therefore conclude that with this methodology we could not detect any alterations in 
ceramide transport in VAPB-downregulated cells. A potential CERT-defect may be masked by the 
vesicular transport of ceramide, as the two pathways could not be distinguished by this technique. 
 
(iii). Analysis of neurite extensions 	  
 VAP proteins are involved in the extension of neurites thanks to their binding to protrudin (see 
Introduction). As illustrated in Section 4.2.2, we assessed that VAPB-downregulated clones extend long 
neurites following differentiation with retinoic acid for six days (Fig. 4.13), indicating that VAPB 
silencing does not completely prevent neutite extension. However, we wanted to perform a more precise 
analysis to check the presence of subtle defects that could not be appreciated by a qualitative experiment.  
 To this end, we quantitatively analyzed neurite length in shRNA-VAPB, vector-only clones and 
untransfected cells. We chose to differentiate them both for six and three days, in order to analyze also an 
intermediate time point. We performed the immunofluorescence analysis by staining cells for tubulin, 
which allowed a clear visualization of both cell body and neurites. As readout, we assessed the percentage 
of cells with at least one neurite longer than 100 μm. As can be observed in Fig. 4.17, both shRNA-
VAPB clones had a lower percentage of cells with neurites longer than 100 μm and this situation was 
present both at three and six days of differentiation.  
 This experiment shows that both mild and strong VAPB downregulation cause a reduction in 
neurite extension during NSC34 differentiation. 
4.2.4 Summary of the results regarding VAPB-downregulated NSC34 
 In this chapter I analyzed the results obtained with VAPB-downregulated NSC34. After first 
describing the generation of such cells, I checked that they can be differentiated following retinoic acid 
treatment and next used them for experiments regarding lipid transport and neurite extension. Regarding 
lipid transport, I assessed that 90% VAPB downregulation increased the amount of the phosphoinositide 
PI4P in the Golgi, but it apparently did not alter the transport of ceramide from the ER to the Golgi. 
Finally, we obtained very interesting results regarding neurite extension, where both mild and strong 
VAPB downregulation were able to reduce the development of protrusions. 
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Figure 4.16: ceramide transport is not delayed in a shRNA-VAPB clone. 
Analysis of Bodipy-Ceramide transport performed with shRNA-VAPB clone #1 and vector-only clone #16. A: 
representative immunofluorescence images of ceramide transport. After loading with Bodipy-ceramide, cells where 
either fixed immediately (time=0) or after a 10 minute incubation to allow ceramide trafficking. Cells are stained 
with Bodipy-Ceramide (green) and DAPI (blue). Scale bar: 20 μm. B: quantification of the percentage of cells with 
visible ceramide accumulation in the Golgi. Graph shows mean ± SD from three independent experiments. 
Approximately 120-150 cells were counted for each condition. No significant difference was obtained following 
Student’s t Test (Excel). C: immunofluorescence analysis of the 488 channel of cells treated or untreated with 
Bodipy-Ceramide. Middle and right panel show the same field of untreated cells (the right one was digitally 
enhanced to show GFP staining).  Scale bar: 20 μm. 
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Figure 4.17: VAPB-downregulated clones show reduced neurite extension. 
A: representative immunofluorescence images of untransfected and shRNA-VAPB clone #1 cells in basal 
conditions and after three and six days of differentiation. Cells were stained with tubulin (red) and DAPI (blue). 
Scale bar: 100 μm. B: quantification of the percentage of cells with a least one neurite longer than 100 μm. Graph 
shows mean ± SEM from three independent experiments. For each condition, 5-7 images, comprising approximately 
250-350 cells, were acquired at low magnification (10x objective) and the cells were manually classified according 
to neurite length. * p<0,05; ** p<0,01 obtained using two-way ANOVA (Graphpad Prism). 
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5. Discussion 
 
 Among the identified ALS-linked genes, the one coding for VAPB is rare. However, the 
observation that VAPB levels are decreased in sporadic ALS patients and in mutant SOD1 transgenic 
mice is consistent with a more general role of the VAPs in motor neuron pathophysiology (Anagnostou et 
al., 2010) (Teuling et al., 2007). Thus, the clarification of the cellular effects of the mutant gene could 
bring important insights into the molecular pathogenesis of ALS.  
 The published studies with cell and animal models that have addressed the pathogenic mechanism 
of mutant VAPB have suggested that various mechanisms may be at play, but have left many questions 
unanswered. Notably, it has not been clear whether the loss of one wt VAPB allele is in itself sufficient to 
cause motorneuronal degeneration (haploinsufficiency effect), or whether the expression of the mutant 
protein is required for pathogenesis. In my thesis, I have addressed this problem by using two 
complementary cell models: HeLa and NSC34 cell lines expressing P56S-VAPB at moderate levels, and 
NSC34 cells strongly or partially silenced for VAPB expression. I discuss these two parts of my thesis in 
separate sections. 
5.1. Lack of effect of P56S-VAPB expression on proteostasis and protein 
transport. 
 As explained in the Introduction, the expression of P56S-VAPB from one allele could be 
pathogenic (and thereby transmitted by dominant inheritance) by two different mechanisms: a toxic gain 
of function or a dominant negative mechanism, by which wt VAPB, VAPA and/or other interacting 
partners would be sequestered into inclusions by mutant VAPB. Regardless of the mechanism, the 
question is whether expression of the mutant protein is or is not a necessary ingredient of P56S-VAPB-
linked fALS.  The results on this question have been so far contradictory, depending on whether cellular 
or animal model studies are considered.  
 A number of cellular studies have demonstrated sequestration of the VAPs and of other 
interacting proteins into P56S-VAPB aggregates (Teuling et al., 2007), with consequent interference in 
fundamental processes, such as intracellular transport (Prosser et al., 2008), as well as a general 
interference in proteostasis (Moumen et al., 2011). On the other hand, transgenic mouse models on a wt 
VAPB genetic background have failed to recapitulate the human disease (see the Introduction for a more 
detailed description of the mouse models). There are two possible explanations for the discrepancy 
between the cell and mouse studies: (i) in the cell studies P56S-VAPB was heavily overexpressed, so that 
the observed effects would not be relevant to cells in which the mutant protein is the product of a single 
allele; or (ii) the mouse, possibly because of its short life span, cannot provide a suitable model for ALS8, 
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implying that P56S-VAPB expression is harmful to motor neurons, but that the mouse doesn't give us the 
time to appreciate the incurred damage. 
 To re-investigate the effects of P56S-VAPB when expressed chronically at moderate levels, we 
turned to cell lines expressing mutant VAPB under the control of a Tet-repressible promoter. In 
Doxycycline-free medium, these cells express P56S-VAPB at levels only 2-3 fold higher than the 
endogenous protein (Fasana et al., 2010) (Papiani et al., 2012) and reach this steady state condition 
gradually over a period of several days after removal of the antibiotic from the medium. Using these cells, 
my laboratory previously demonstrated that P56S-VAPB is unstable in comparison to the wt protein, and 
that its degradation is mediated by the proteasome and involves the participation of a key ERAD player, 
the AAA ATPase p97 (Papiani et al., 2012).  In the first part of my thesis research, I continued the 
investigation on the mechanism of degradation of P56S-VAPB inclusions as well as on their possible 
toxic effects on the cells.  
 First, I confirmed that under basal conditions mutant VAPB inclusions are cleared by the 
proteasome, both in HeLa and in the model motoneuronal NSC34 cell line; in addition, I showed that 
autophagy, when stimulated, can further enhance degradation of the mutant protein. Thus, the inclusions 
can be degraded by both major degradative pathways of the cell; these results predict that, under 
conditions in which the cell potentiates autophagy, mutant VAPB inclusions will not become 
overrepresented in comparison to other compartments targeted by autophagy. 
 I next investigated whether P56S-VAPB inclusions interfere with two fundamental processes: (i) 
protein degradation mediated by the proteasome and by autophagy; and (ii) protein transport through the 
secretory pathway.  
 Moumen reported that transient overexpression of either wild-type or mutant VAPB results in an 
increase of polyubiquitinated proteins and stabilization of three different proteasomal substrates, among 
which the classical ERAD substrate CD3δ (Moumen et al., 2011). However, in HeLa Tet-Off cells, 
clearance of CD3δ, whose degradative pathway shares with the one of P56S-VAPB the involvement both 
of the proteasome and of p97, was unaffected by the expression of the mutant protein.  
 Autophagic dysfunction has been described in ALS, and is currently thought to be a major player 
in ALS pathogenesis (reviewed in (Chen et al., 2012), (Navone et al., 2015)). However, the effect of 
P56S-VAPB inclusions on autophagic flow had not yet been investigated. I found that autophagy, 
stimulated either pharmacologically or by starvation, was unaffected by P56S-VAPB expression. Hence, 
it appears that cells can adjust the capacity of their degradative machinery to cope with moderate levels of 
mutant VAPB without consequent disturbances in proteostasis.  
 As summarized in the Introduction, a fundamental process in which the VAPs are implicated is 
intracellular transport through the secretory pathway, but contrasting results have been reported on the 
effect of P56S-VAPB expression on this process. In CHO cells, (Prosser et al., 2008) found a strong 
interference of overexpressed P56S-VAPB (and also of overexpressed wt VAPA) with VSVG transport, 
whereas no delay of the transport of the same secretory membrane cargo was detected by Teuling et al. in 
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primary hippocampal neuronal cultures (Teuling et al., 2007). With the HeLa Tet-Off cells, I found that 
neither transport of VSVG from the ER to the Golgi nor its export to the cell surface were altered by the 
presence of P56S-VAPB inclusions. I conclude that cells can maintain secretory pathway function in the 
presence of P56S-VAPB inclusions, notwithstanding their close physical proximity to the Golgi apparatus 
demonstrated here. Of course, I cannot exclude at present that other cargoes and other cell types may be 
more sensitive to the presence of P56S-VAPB inclusions. Further studies are required to generalize my 
findings to other contexts. 
 The results of the first part of my thesis, showing a lack of interference of moderate levels of 
P56S-VAPB with basic cellular functions, are consistent with the outcome of analyses of transgenic 
animals. Furthermore, P56S-VAPB is unstable, as demonstrated by studies carried out previously in my 
laboratory (Papiani et al., 2012), and this instability likely explains the lack of detectable VAPB 
inclusions in ALS8 patients' motor neurons generated from iPSCs (Mitne-Neto et al., 2011). In support of 
the relevance of the in vitro studies to the in vivo situation, (Aliaga et al., 2013) detected lower levels of 
mutant than of wild-type protein in the brains of transgenic mouse strains that had comparable levels of 
mRNA expression. Thus, it is feasible that in the heterozygote -P56S/wt - individual, mutant VAPB 
inclusions never reach the high levels required for them to exert a damaging effect on motor neurons.  
 Taking into account my results combined with the above considerations, I decided to investigate 
ALS8 genesis from a different perspective, i.e., to analyze the effect of reduction of VAPB levels on 
cellular physiology in the absence of expression of the mutant protein. 
5.2. Effect of VAPB downregulation on motorneuronal physiology. 
 For these studies I chose to work with the motorneuronal-like cell line NSC34.  This is a mouse 
cell line created by fusion of a neuroblastoma line with spinal cord primary motor neurons, and currently 
represents the best available characterized cell line with motorneuronal characteristics (Cashman et al., 
1992). I first analyzed the ability of NSC34 cells to differentiate into cells with more pronounced 
motorneuronal characteristics, using a recently published protocol (Maier et al., 2013).   
 Among the observations that I made on the differentiation process, the one regarding GM1 is of 
particular interest. This glycoshingolipid was found mainly on intracellular vesicles positive for the late 
endosome/lysosomal marker LAMP1 under basal conditions. Instead, after differentiation, most of the 
GM1 was seen on the cell surface. A recent study has implicated late endosomes as the carriers of 
membranes to extending neurites ((Raiborg et al., 2015a) -see also below). Thus, the intracellular GM1 
pool in the non differentiated cells may be part of a storage compartment that is recruited during the 
neurite extension process triggered by differentiation.  
 A second interesting finding is that the VAPs, especially VAPB, are upregulated during 
differentiation, suggesting that they play a specific role in motorneuronal differentiation/physiology, and 
encouraging me to investigate the effect of VAPB downregulation on phenomena in which the VAPs 
have been implicated. Indeed, it has already been reported that VAPB is upregulated following iPSC 
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differentiation into motorneurons (Mitne-Neto et al., 2011). I was able to generate two NSC34 clones 
silenced for VAPB; in one of the clones, VAPB expression was reduced to about 50% of the control cells, 
providing a model for haploinsufficiency; the other clone had more strongly reduced VAPB levels, 
approaching homozygous loss of function. I used these two cell lines to investigate the effect of VAPB 
depletion on (i) ceramide transport, (ii) PI4P levels in the Golgi, and (iii) neurite extension during the 
differentiation process. 
(i). Ceramide transport. 
 
  As explained in the Introduction and Results sections of this thesis, the VAPs are involved in 
ceramide transport from the ER to the Golgi, because of their ability to recruit the ceramide transport 
protein CERT to the ER (Lev, 2010). A delayed ceramide transport, due to VAPB deficiency, could lead 
to an imbalance in the sphingolipid composition of the affected cells, with a predicted excess of 
unprocessed ceramide. Ceramide is known to be neurotoxic and accumulation of ceramide has also been 
reported in the spinal cord of sALS patients (Cutler et al., 2002).  
 To investigate the effect of VAPB depletion on ceramide transport, I applied a sensitive 
microscope assay, in which a fluorescently labeled ceramide is first accumulated in the ER, and then 
allowed to be transported to the Golgi (Toth et al., 2006). By this assay, I could not detect an effect of 
near complete VAPB depletion on ceramide transport. To be noted, the assay was effective in revealing a 
slowdown of ceramide transport in cells transiently overexpressing P56S-VAPB at high levels (results not 
shown). 
 The results obtained with the NSC34 clones might seem at variance with those obtained by 
(Peretti et al., 2008), who demonstrated alterations in CERT localization and sphingomyelin levels in 
HeLa cells silenced for both VAPA and B.  It is possible that in NSC34, VAPA is present in sufficient 
amounts to guarantee normal CERT-mediated ceramide transport. It is also possible that in these cells, the 
vesicular route of ceramide transport is the more important one, so that inhibition of LTP-dependent 
transport is difficult to detect. 
(ii). PI4P levels in the Golgi.  
 
As detailed in the Introduction, the VAPs play a crucial role in regulating phosphoinositide levels 
within the ER-Golgi compartments. The role of the VAPs is intimately connected to the LTP OSBP, 
whose function has recently been elucidated (Mesmin et al., 2013). OSBP, which forms a MCS between 
the ER and the trans Golgi, can bind both sterols and PI4P via its ORP domain. The ORP domain should 
not be confused with the PH domain which, by binding PI4P, serves to anchor OSBP to the Golgi. Instead 
the ORP domain is used for transport of both cholesterol and PI4P. At the ER, it picks up cholesterol, 
because PI4P levels are low; at the trans Golgi, it exchanges cholesterol for PI4P, because its affinity for 
the phosphoinositide is higher than for sterols, and because PI4P levels are high in the trans Golgi. 
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Release of PI4P to the ER occurs passively, driven by the concentration gradient of the lipid. The 
concentration of PI4P is indeed kept low by the activity of the ER phosphatase Sac1. As already 
mentioned, the VAPs interact with Sac1 and enhance its activity (Forrest et al., 2013). The entire cycle 
drives export of cholesterol from the ER, using the energy stored in PI4P; in the cycle, the VAPs play a 
dual role: they provide a docking site for OSBP, and they activate Sac1 to dispose of the back-transported 
PI4P (see Fig. 5.1).   
 The predicted consequence of VAP depletion should be interruption of the OSBP cycle with a 
consequent accumulation of PI4P in the Golgi as a result of both impaired docking of OSBP on the ER 
and reduced Sac1-mediated dephosphorylation of PI4P that would disrupt its concentration gradient. Very 
interestingly, in the NSC34 clone with near complete VAPB knockdown, I observed the predicted effect 
both in non-differentiated and in differentiated cells, indicating that, at variance with the results obtained 
on ceramide transport, the VAPA pool alone is not sufficient to guarantee phosphoinositide balance. This 
result reflects what has been observed in Drosophila, where DVAP (the homologue of both VAP 
proteins) downregulation increases PI4P levels (Forrest et al., 2013). Although I did not see an effect in 
the clone with partial VAPB knockdown, one might speculate that a small degree of PI4P accumulation 
in the Golgi could also be present in cells expressing wt VAPB from one allele, but be undetected in my 
assay.  
 
 
	  
                      Figure 5.1: Schematic representation of PI4P cycle at ER-Golgi MCS. 
 
 
 
 An imbalance in PI4P distribution between the Golgi and the ER compartments could have far 
reaching effects on cellular physiology. Phosphinositides are key molecules in determining compartment 
identity (Di Paolo and De Camilli, 2006), so an increase in PI4P would alter the Golgi identity kit. There 
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is a vast number of PI4P interacting proteins that are involved in fundamental cellular processes, like 
vesicular transport from the Trans Golgi Network.	  Four-­‐Phosphate-­‐adaptor	  Protein	  (FAPP) 1 and 2 are 
an example of such proteins: they are recruited to the TGN thanks to their binding to both PI4P and the 
small GTPase Arf1 and regulate Golgi to PM trafficking (Godi et al., 2004). In addition, FAPP2 has a 
role in intra-Golgi non-vesicular transport of GlucosilCeramide from cis to trans Golgi, where it is 
converted into Globosides, a class of complex glycosphingolipids (D'Angelo et al., 2013). Finally, the 
increase in Golgi PI4P is likely to alter the concentrations of other downstream phosphoinositides, like 
PI4,5P2 and PI3,4,5,P3. 
(iii) Neurite extension during the differentiation process. 
 
 Among their many functions, the VAPs have been implicated in neurite extension (see 
Introduction), so it seemed of great interest to determine whether depletion of VAPB alone would have an 
effect on this process in a motorneuronal background. As a matter of fact, it has been reported that 
downregulation of VAPA, but not VAPB, strongly reduces neurite extension in the pheocromocytoma 
cell line PC12 (Saita et al., 2009). While visual inspection of the differentiated VAPB-silenced cells did 
not show obvious differences from the control cells, quantitative analysis revealed that fewer silenced 
than control cells had long neurites (>100 μm) at three and at six days of differentiation. This effect was 
statistically significant both for the partially and for the near completely silenced clone.   
The mechanisms by which the VAPs promote neurite extension could be indirectly related to 
their roles in protein and lipid transport within the secretory pathway (Kuijpers et al., 2013b). However, 
recent evidence has uncovered a more direct role of the VAPs in the process, mediated by their 
interaction with the FFAT-containing protein protrudin (Saita et al., 2009). Protrudin, an ER 
transmembrane protein, appears to be involved in neurite extension by promoting focal contacts between 
the ER and late or recycling endosomes; interaction with late endosomes is mediated by its FYVE domain 
(which binds PI3P, the signature phosphoinositide of late endosomes and lysosomes) and the interaction 
with Rab7 (Raiborg et al., 2015a) (see Fig. 1.5); the interaction with recycling endosomes would instead 
be driven by interaction with Rab11 (Shirane and Nakayama, 2006). Protrudin is thought to recruit the 
microtubule motor KIF5 to the endosomes, permitting their transport to the cell periphery along 
microtubules. Both recycling and late endosomes would thus provide a source of membrane to be 
delivered to the growing tips of neurites by exocytosis. My observations on the GM1 distribution in non-
differentiated cells fit well with the previously described role of late endosomes in neurite extension 
(reviewed in (Sann et al., 2009)). 
 Since protrudin is an ER resident transmembrane protein, the open question is the role of the 
VAPs in the process of protrudin-dependent neurite extension. Clearly, the VAPs are not required to 
recruit protrudin to the ER, as is the case for LTPs. The observation that the FFAT sequence of protrudin 
is required for its activity in neurite extension (Saita et al., 2009) indicates that direct interaction between 
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the VAPs and protrudin is required. This interaction could result in modulation of protrudin's 
conformation, making it competent for kinesin recruitment. 
Whatever the mechanism by which the VAPs support protrudin function, my observation that 
depletion of VAPB alone decreases neurite extension in NSC34 cells has implications for motorneuronal 
cell biology and viability as well as for ALS pathology. As mentioned above, previous studies on VAP 
function have been carried out by silencing both VAP isoforms (Teuling et al., 2007) (Peretti et al., 2008) 
or VAPA alone (Saita et al., 2009). My results demonstrate for the first time, an effect of VAPB depletion 
in the presence of normal levels of VAPA. In other words, VAPB plays a role in neurite extension, whose 
loss is not compensated by VAPA, a phenomenon which could be explained by insufficient amounts of 
VAPA in NSC34 cells and/or by a function unique to VAPB in motorneuronal cells, not replaceable by 
VAPA. 
Experiments, in which my NSC34 clones will be transfected with siRNA resistant VAPB or 
VAPA, are currently being carried out, and may clarify this issue.  
 A surprising observation of my experiments was that the two NSC34 clones, which have a 
different degree of VAPB silencing, showed a similar decrease in neurite extension. This finding is 
somewhat difficult to explain. As neurite extension surely involves more than one mechanism, one might 
hypothesize that the VAPB-dependent pathway is exquisitely sensitive to VAPB levels, so that a ~50% 
reduction exerts already the maximum inhibitory effect. Be this as it may, the strong effect seen with 
clone #6, which has a ~50% reduction in VAPB levels, is consistent with the idea that VAPB 
haploinsufficiency could trigger motorneuronal degeneration. Indeed, the process of axon and dendrite 
maintenance is presumably closely related to the one of neurite extension during differentiation (Sann et 
al., 2009) (Lee et al., 2010). VAPB haploinsufficiency could thus result in insufficient membrane delivery 
to motorneuronal extensions, a process that could cause muscle denervation and disease onset and 
progression.  
5.3. Conclusions and perspectives 
 Taken together, the results of my thesis support the hypothesis that ALS8 is caused by VAPB loss 
of function. I was unable to show any interference of P56S-VAPB inclusions with proteostasis or with the 
secretory pathway, whereas VAPB silencing did have phenotypic effects in NSC34 cells with regards 
both to phosphoinositide balance and to neurite extension. The latter observation opens a number of 
questions that will hopefully be addressed in the future. First, to exclude off-target effects of VAPB 
silencing, it will be crucial to express siRNA-resistant VAPB in our clones and assess whether the altered 
phenotype is reversed. I am currently in the process of carrying out these experiments. Second, it will be 
interesting to unravel the contributions of the two VAP isoforms in neurite extension and 
phosphoinositide metabolism: will VAPA overexpression in our silenced clones be as effective as VAPB 
in reversing the phenotype? It would, of course be interesting to generate VAPA silenced NSC34 clones; 
this could probably be done more easily with CRISPR technology than with shRNA, as done in this 
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study. It should also be interesting to determine the absolute levels of the two VAP isoforms in NSC34 
cells: can the effect of VAPB silencing be explained simply by very low levels of VAPA in these cells? 
And, finally, since VAPs are partially depleted both in mutant SOD1 mice and in cases of sALS, it should 
be interesting to investigate whether an increase in VAP levels could partially reverse the pathology 
caused by other mutations in ALS animal models. A positive result might suggest novel strategies for 
therapeutic interventions for this fatal disease. 
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